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Abstract 
An increasing number of men are developing a lethal, non-androgen 
receptor (AR) driven form of prostate cancer (PCa) known as aggressive variant 
prostate cancer (AVPC). Therapeutic options for AVPC are limited, and the 
development of novel therapeutics is significantly hindered by the inability to 
accurately monitor the disease through imaging. This underscores the critical need 
to develop improved imaging agents for AVPC. Targeted imaging agents, such as 
those developed for prostate-specific membrane antigen (PSMA) have made 
significant progress in imaging metastatic prostate adenocarcinoma; however, 
numerous studies have shown that non-AR driven prostate cancer does not 
express PSMA. Thus, there is an urgent unmet need to identify novel antigens and 
targeted imaging agents for the detection and monitoring of this lethal form of PCa.  
In these studies, we have identified the pentaspan transmembrane 
glycoprotein, CD133, as a targetable antigen that is overexpressed on the surface 
of non-AR driven, neuroendocrine-differentiated prostate cancer. Additionally, we 
have developed a novel antibody, termed HA10 IgG, which was found to bind to a 
glycosylation-independent epitope on CD133. HA10 IgG was validated in 
numerous cell lines and demonstrated similar or more accurate binding to CD133 
when compared to a frequently used commercial antibody in vitro. To assess the 
imaging potential of HA10 IgG, the antibody was labeled for near-infrared and 
positron emission tomography imaging. Our CD133 probe was validated in 
imaging studies and shown to be highly selective for CD133-expressing PCa cells, 
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suggesting its potential as a non-invasive imaging agent for lethal, non-AR-driven 
AVPC.   
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Impact of Prostate Cancer 
Prevalence and Mortality  
Prostate cancer (PCa) is the most common non-cutaneous cancer in 
American men. Approximately 11.6% of men will be diagnosed with PCa within 
their lifetime and the American Cancer Society currently estimates that there will 
be approximately 174,650 new cases of PCa in 2019 alone (1). National 
expenditures for PCa care reached approximately $15.3 billion in 2018, signifying 
the tremendous personal and economic impact PCa has on society.  Despite its 
high prevalence, PCa is a relatively treatable disease with roughly 98% of patients 
achieving a 5-year survival (1). Unfortunately, if the cancer has progressed to 
metastatic disease, the 5-year survival rate drops significantly to a striking 30% (1, 
2), indicating the importance of developing better theranostic agents to detect and 
treat metastatic PCa.  
Progression of Prostate Cancer with Response to Therapy  
 There are three primary stages of PCa progression: 1) localized, 2) regional, 
and 3) distant disease. Localized PCa is defined as PCa which has not left the 
confines of the prostate gland. Regional PCa is when the cancer has only spread 
to neighboring organs such as the seminal vesicles or nearby lymph nodes and 
distant PCa is described as PCa which has spread to distant sites such as the 
bones, viscera, and/or distant lymph nodes. Approximately 90% of PCa cases are 
identified in the localized and regional stages and the average age of diagnosis is 
approximately 66 years old (2). Since PCa is often a slow growing disease, many 
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men who are older or present with additional health problems will never receive 
treatment for their cancer. This is because the treatment for slow growing, local 
PCa can often times pose more risk to the patient’s overall health than the cancer 
itself (3). The current standard of care in these cases is active surveillance in which 
the cancer is monitored for signs of rapid progression and metastasis. Monitoring 
for signs of PCa progression may include prostate-specific antigen (PSA) blood 
tests, digital rectal exams (DREs), biopsies, and potentially imaging (4-6). 
 If the initial screening or continuous active surveillance suggests that the 
PCa is suspected to pose a greater threat than treatment, such as in the cases of 
a more aggressive pathology or presentation in a younger man, then the first line 
of treatment is usually surgery, radiation therapy, or a combination of the two. 
Surgery, often referred to as a prostatectomy, includes direct removal of the 
prostate gland and sometimes other surrounding tissues that the cancer may have 
spread to. Alternatively, radiation therapy uses high-energy radiation to kill the 
remaining cancer cells. There are two main types of radiation therapy, external-
beam radiation therapy (EBRT) and internal radiation therapy (IRT). The major 
difference between these two types of therapy is the location of the radiation 
source. EBRT uses an externally-located X-ray producing machine to focus 
radiation onto a specific cancerous region of the body, while IRT requires the 
implantation of radioactive sources directly into the cancerous regions of the body 
(3). While surgery and radiation therapy are often curative for most men, 
approximately 20-30% of patients develop PCa recurrence.      
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 Androgen deprivation therapy (ADT) is the current standard of care for men 
that present with recurrent and/or metastatic disease and as a neoadjuvant to 
EBRT for men with localized and/or regional disease (3, 7). Re-activation of the 
androgen receptor (AR) signaling axis aft ADT is a well-known key player in PCa 
progression. Androgens, such as testosterone and dihydrotestosterone, bind to 
AR which promotes dimerization, nuclear translocation, and subsequent gene 
activation and cancer cell growth (Figure 1) (8). ADT aims to prevent AR signaling 
by actively reducing the number of circulating androgens that are available to bind 
to and activate AR (9-11). Most men display a transient reduction of PCa 
symptoms, including lowered PSA and tumor regression, however, most of these 
patients eventually progress to castration-resistant PCa (CRPC) which is a 
hormone-insensitive form of the disease (Figure 2) (12, 13).  
 CRPC is a biochemical (rising PSA) or clinical (new or larger lesions) 
progression of the disease despite castrate levels of androgens in the blood. 
Strategies to combat CRPC often involve cutting off alternate mechanisms of AR 
signaling using second generation anti-androgens. Two of the most notable 
second-generation anti-androgens are enzalutamide which directly blocks AR and 
abiraterone which prevents adrenal gland hormone synthesis. While second 
generation anti-androgens were initially approved for CRPC, recent Phase II and 
III trials have documented the success of these agents in nonmetastatic PCa 
indicating a shift in the treatment landscape (14, 15). Unfortunately, many patients 
display inherent resistance to these therapies, and others acquire resistance after  
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Figure 1. Schematic of the AR signaling axis and PCa progression. Free 
testosterone or dihydrotestosterone enters the prostate cells and binds to AR.  
AR dissociates from heat shock proteins (HSPs) and dimerizes to facilitate 
nuclear translocation. Dimerized AR binds to androgen-response elements in 
the promoter regions of target genes which leads to biological responses 
including increased growth, survival, and the production of PSA. This image was 
reproduced from previous publications (8, 16). 
AR 
HSP 
AR AR 
Testosterone 
DHT 
5α-reductase 
AR AR 
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months of use. Additionally, in 2010, the U.S. Food and Drug Administration (FDA) 
approved the immunotherapy agent, Sipuleucel-T, for treatment of advanced PCa 
(17). Although Sipuleucel-T did display a mild survival benefit in CRPC patients, 
there seemed to be very little effect on slowing disease progression (18-20). 
Similarly, chemotherapy has also been shown to prolong overall survival but is 
often paired with unpleasant side effects and reduced quality of life. This lethal 
stage of the disease continuum is known as aggressive variant PCa (AVPC) and 
can occur with or without AR re-activation (Figure 2).   
More specifically, AVPC is a broad-spectrum form of PCa defined as CRPC 
with at least one of the following features: 1) histologic evidence of small-cell 
neuroendocrine differentiated PCa (pure or mixed), 2) the presence of exclusively 
visceral metastases, 3) radiographically predominant lytic bone metastases by 
plain x-ray or CT scan, 4) bulky (≥ 5 cm) lymphadenopathy or bulky (≥5 cm) high-
grade (Gleason ≥ 8) tumor mass in prostate/pelvis, 5) low PSA (≤ 10 ng/mL) at 
initial presentation (prior to ADT or at symptomatic progression in the castrate 
setting) plus high volume (≥ 20) bone metastases, 6) presence of neuroendocrine 
markers on histology (positive staining of chromogranin A (CHGA) or 
synaptophysin) or in serum (abnormal high serum levels for CHGA or gastrin-
releasing peptide) at initial diagnosis or at progression, plus any of the following in 
the absence of other causes: (a) elevated serum LDH (≥ 2 × ULN), (b) malignant 
hypercalcemia, (c) elevated serum CEA (≥ 2 × ULN), 7) short interval (≤ 6 months) 
to androgen-independent progression following the initiation of hormonal therapy 
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with or without the presence of neuroendocrine markers (21-23). Due to 
deficiencies in previously used advanced PCa definitions, such as anaplastic, AR-
independent, treatment-induced, or neuroendocrine PCa, AVPC has been 
adopted as a term which includes all of the aforementioned pathologies (22). 
Despite the fatal prognosis of AVPC, the currently available imaging strategies are 
often insufficient to accurately detect AVPC lesions and evaluate overall disease 
progression. The lack of proper diagnostic agents is a major clinical barrier to 
developing effective therapeutics for this disease. Due to the heterogeneity of 
AVPC, it has been exceedingly challenging to identify targetable biomarkers that 
are reliably expressed on the lesions of AVPC patients. Further efforts are urgently 
needed to identify biomarkers of AVPC and define their relevance in specific AVPC 
patient populations for improved therapeutic and diagnostic (theranostic) 
development.    
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Figure 2. Chart displaying PCa progression with response to therapy. High-
risk local or metastatic disease are treated with ADT. While initially responsive, 
patients eventually develop CRPC. Second generation anti-androgens are given 
to further prolong lifespan, however, patients eventually acquire resistance to 
these therapies as well and progress to lethal AVPC. Lethal AVPC can develop 
with or without AR-reactivation. The only treatment options available for AVPC 
are chemotherapy and palliative care, neither of which can cure the disease. 
This image was reproduced from previous literature (24).    
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Current Detection and Disease Monitoring Approaches  
 Screening and Staging of Prostate Cancer  
 Early signs of PCa are often identified by preliminary screening 
assessments such as the PSA blood test and the DRE. The U.S. Preventative 
Services Task Force recommends screening for PCa in men between the ages of 
50-54 unless there are predefined risk factors that require earlier screening (Table 
1). Similarly, regular screening may continue up to the age of 69 on a case by case 
basis (25, 26). While the use of PSA blood tests and DREs has been highly 
effective at identifying PCa during the first round of screening, these two tests are 
also prone to false positives (27-30). PSA is an androgen-regulated protease that 
is released by the secretory epithelial cells of the prostate gland. In healthy men, 
the primary function of PSA is to liquify semen during ejaculation and facilitate 
better sperm transport for reproduction, thus blood PSA levels remain relatively 
low. However, the basement membrane is often disrupted in PCa which results in 
significantly more PSA leaking into the blood (31). While high PSA levels are often 
observed in PCa patients, elevated blood PSA levels may also indicate various 
non-cancerous conditions as well, such as prostatitis, benign prostatic hyperplasia, 
urinary tract infections, and even prostate stimulation (32). Correspondingly, DREs 
are a blind exam in which a physician can manually palpate the prostate through 
the rectum and thus will not provide enough evidence to confirm a PCa diagnosis. 
An abnormal DRE exam may include observed nodule formation, asymmetric 
growth of the prostate, age inappropriate enlargement, or increased signs of 
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Table 1. Recommended PCa screening ages.  This image was reproduced 
from previous literature (25, 26). 
Begin Screening 
at Age: 
Reason: 
40 You have a family history of PCa 
45 You are of African American decent 
50 You have no family history and are not African American  
55-69 Discuss with doctor on an individual basis 
70+ Screening is not recommended 
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inflammation (33). When abnormalities are detected through one or both of these 
preliminary exams, a transrectal ultrasound (TRUS) and biopsy are provided to 
confirm the PCa diagnosis (26, 34).  
The TRUS procedure requires the insertion of a small probe into the rectum 
which is used to visualize the prostate gland. TRUS is most often used for image 
guided prostate biopsies, however, it may also be used to measure the size of the 
prostate and make treatment decisions accordingly (34, 35). For the biopsy, most 
physicians will take 12 samples from various regions of the prostate to gain an 
accurate assessment of the overall pathology of the prostate. Pathologists analyze 
the biopsy samples and determine prostate tissue abnormality using the Gleason 
scoring system which signifies normal prostate tissue as grade 1 and very 
abnormal/cancerous tissue as grade 5. To account for heterogeneity within the 
prostate tissue, a grade is obtained from 2 separate regions of the tissue; the sum 
of the two grades yields the Gleason score (grade of region 1 + grade of region 2 
= final Gleason score). Additionally, the grade of region 1 is the most frequently 
identified grade throughout the tissue sampled, thus Gleason scores of 3+4=7 are 
often less aggressive than 4+3=7 (36). Gleason scores can range anywhere from 
2 to 10, however, scores below 6 are rarely indicative of PCa (34).  
Imaging of Prostate Cancer 
Once a PCa diagnosis has been confirmed, imaging tests are often used to 
assess the extent of cancer spread. CT and magnetic resonance imaging (MRI) 
may be used to visualize the soft tissues surrounding the prostate if the PCa is 
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suspected to be regionally located (34), however, both of these conventional 
imaging modalities are highly limited by their insensitivity for small nodal lesions 
and inability to detect bone lesions (37). The skeletal system is the second most 
common site for metastasis of PCa, surpassed only by the lymph nodes. In fact, 
approximately 80-90% of CRPC patients will develop bone metastases over the 
course of the disease (38-40). Bone scintigraphy (BS) using technetium-99m 
methyl diphosphonate (99mTc-MDP) is the current standard of care for detecting 
bone metastases in these patients due to its low energy, short half-life, and 
widespread availability (41, 42). Despite much of the initial success with 99mTc-
MDP, most of the current guidelines using this imaging agent are based on 30-
year old studies (37, 43, 44). Additionally, imaging with CT, MRI, and/or 99mTc-
MDP are not sufficient to adequately identify visceral metastases that may be 
present in AVPC patients and thus are not accurate diagnostic and disease 
monitoring modalities for PCa patients in this stage of the disease.  
Recent studies using positron emission tomography (PET)/CT have 
indicated that PET imaging may be superior over the current standard of care. The 
two most common PET radiotracers are [18F]-fluorodeoxyglucose (FDG) and [18F]-
sodium fluoride (NaF). While FDG has been highly effective in the diagnosis and 
monitoring of other cancers (45, 46), it has been deemed unreliable and lacking 
specificity in PCa and therefore is not frequently used (Table 2) (37). Alternatively, 
recent meta-analyses have shown that NaF is more specific for bone lesions 
compared to 99mTc-MDP and can also detect some nodal lesions in late-stage  
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Table 2. Current clinical indication of PET radiotracers and their regulatory 
status.  
Tracer Target Indication Regulatory 
Status 
FDG Glucose 
metabolism 
minimal use in PCa, only 
used when other tracers 
are not available  
FDA approved, 
August 5, 2004 
NaF Osteoblastic 
activity 
Known or suspected 
osseous lesions 
FDA Approved, 
January 26, 
2011 
11C-choline 
 
Cell membrane 
metabolism 
High-risk staging, 
biochemical relapse at high 
PSA levels 
FDA approved, 
September 12, 
2012 
11C-acetate Fatty acid 
synthesis 
Useful for monitoring 
recurrence after focal 
therapy, unreliable in 
biochemical recurrence, 
not as effective as other 
agents on the market 
Under 
investigation  
Fluciclovine Amino acid 
transport 
High-risk staging, 
biochemical relapse at high 
PSA levels 
FDA approved, 
May 27, 2016 
FDHT AR Early stage disease 
detection and prognosis 
Under 
investigation 
anti-PSMA 
ligands 
PSMA Multiple stages including 
biochemical relapse at low 
PSA 
Under 
investigation 
Abbreviations: FDG, [18F]-fluorodeoxyglucose; NaF, [18F]-sodium fluoride; FDHT: [18F]-
DHT; PSMA, prostate-specific membrane antigen; AR, androgen receptor; PSA, 
prostate-specific antigen   
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CRPC patients, displaying superiority over that current standard of care (42, 47-
49). Unfortunately, the widespread use of NaF is substantially restricted due to its 
lack of availability and reimbursement challenges (50).  
Other PET imaging agents have recently been approved or are currently 
under investigation for PCa detection and monitoring, including 18F/11C-choline, 
11C-acetate, [18F]-fluciclovine, [18F]-DHT (FDHT), and prostate-specific membrane 
antigen (PSMA)-targeted agents (Table 2) (51-55). Three different choline 
radiotracers are currently available for clinical use (18F-fluoroethylcholine, 18F-
fluoromethylcholine, and 11C-choline) although the 18F-choline tracers are still 
under investigation for FDA approval. PCa cells use choline to synthesize a major 
constituent of the cell membrane, phosphatidylcholine, making it a promising target 
for diagnostic imaging (37). Most studies have indicated that choline is highly 
sensitive and specific for detecting lymph node and skeletal metastases in 
biochemically recurrent PCa patients, however, it also has a relatively high false 
positive rate of approximately 20% in nodal disease which is of major clinical 
concern (37, 56, 57). 11C-acetate works similarly to 11C-choline by exploiting the 
idea that PCa cells abundantly convert acetate into fatty acids which are then used 
to produce phosphatidylcholine (37, 58). Despite its similar mechanism of action, 
a meta-analysis of 11C-acetate in PCa revealed that it was not as sensitive or 
specific as 11C-choline and will likely not be used over the newer, more effective 
tracers (59). Fluciclovine, also referred to as FACBC, was recently approved for 
use in men with suspected PCa recurrence. Fluciclovine is an 18F-labeled leucine 
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analog that is taken up by PCa cells through amino acid transporters (37, 51). Like 
the choline and acetate compounds, fluciclovine lacks specificity in early-stage 
PCa and displays more accurate detection during biochemical recurrence (60, 61). 
Some studies suggested that fluciclovine is more specific than choline tracers (62, 
63), however, the disadvantages of this tracer limit its utility including a high false 
positive rate and its inability to fully replace BS to detect bone lesions in patients 
(64). FDHT is a fluorinated DHT molecule that binds directly to AR. Since PCa is 
primarily driven by AR in its early stages, it makes sense that an AR-targeted 
imaging agent would allow for better detection of PCa cells (37). Unfortunately, 
once a patient is treated with an AR antagonist, such as enzalutamide, the imaging 
agent will be displaced and rendered ineffective (65, 66). Similarly, this agent will 
not be if AR is not present such as in the case of AR-indifferent AVPC. Additionally, 
many of the previously mentioned imaging agents have not been tested in AVPC 
patients and have been shown to display prominent physiological uptake in the 
visceral organs of many patients (37, 52, 54, 55). Since AVPC patients are prone 
to metastatic lesions in the viscera, it is critical to develop a targeted diagnostic 
agent to accurately detect these lesions.  
 PSMA is a type II integral membrane glycoprotein that has received a lot of 
interest as a targetable biomarker for individualized PCa imaging and therapy. In 
general, PSMA has been correlated with metastasis, disease recurrence, and 
increased overall aggressiveness of the cancer (67, 68). Consequently, numerous 
efforts have been undertaken to develop PSMA-targeted theranostics for PCa. In 
16 
 
1996, the first anti-PSMA antibody, capromab pendetide or ProstaScint, was 
approved by the FDA as a diagnostic imaging agent for patients with biopsy-proven 
PCa who are at high-risk for pelvic lymph node metastasis and post-prostatectomy 
patients with a rising PSA a high clinical suspicion of metastatic disease (69). 
Unfortunately, ProstaScint was only able to bind to the intracellular epitope of 
PSMA which led to only modest clinical improvements over conventional imaging 
modalities (70, 71). Tremendous efforts have since been made to develop PSMA-
targeted ligands that bind to the extracellular domain of the protein. These efforts 
include the development of the humanized anti-PSMA antibody, J591, which has 
been successful in multiple diagnostic PET imaging and radioimmunotherapy 
clinical trials (72-75). To date, zirconium-89 (89Zr) has been the primary radiotracer 
for assessing the clinical PET imaging capabilities of J591. In fact, a recent study 
demonstrated that 89Zr-J591 was able to accurately detect more bone and soft 
tissue lesions than BS, CT, and FDG-PET imaging, demonstrating its superiority 
over the currently available imaging modalities and radiotracers (76).  
The development of PSMA-targeted ligands has laid the foundation for 
precision medicine in PCa and is working to tailor disease monitoring and 
treatment strategies to particular characteristics of each individual patient’s cancer 
(77). While PSMA is typically correlated with more aggressive disease, it has been 
documented that neuroendocrine differentiation in PCa and prolonged ADT usage 
leads to PSMA suppression (78, 79), both of which are frequent occurrences in 
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AVPC. Therefore, the identification of new biomarkers of AVPC is necessary to 
ensure better diagnosis and disease monitoring in these patients.     
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Current Understanding of CD133 in the Prostate  
CD133 Structure and Function  
Cluster of differentiation 133 (CD133) is a 97-kDa pentaspan 
transmembrane glycoprotein that contains an extracellular N-terminal domain 
(EC1), five transmembrane segments which separate two small intracellular loops 
(IC1 and IC2), two large extracellular loops (EC2 and EC3), and an intracellular C-
terminal domain (IC3) (Figure 3) (80). The two extracellular loops contain nine 
putative N-glycosylation sites; five on EC2 domain and four on EC3 domain (81). 
Glycosylation of CD133 yields a 120 kDa protein and alters the overall tertiary 
structure and stability of CD133 (82-84). Additionally, a few commercially available 
antibodies have been developed for CD133, however, most of them display poor 
efficacy in various assays. The two most commonly used antibodies, CD133/1 and 
CD133/2, only work in certain assays and bind to glycosylated epitopes which will 
be further addressed in Chapter II. Therefore, even these antibodies have limited 
utility in research and are not recommended for preclinical or clinical use.    
The CD133 gene, Prominin 1 (PROM1), is located on chromosome 4 in 
humans and chromosome 5 in mice and is only approximately 60% homologous 
from primates to rodents (84, 85). Transcription of human CD133 is driven by five 
alternative promoters, three of which are located on CpG islands and are partially 
regulated by methylation. These promoter regions often result in alternative 
splicing of CD133 mRNA, resulting in CD133 isoforms with potentially unique roles 
(83, 86-88). 
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Figure 3. Schematic of the CD133 topology and putative epitopes of 
commercially available CD133 antibodies. The five transmembrane 
glycoprotein contains two large extracellular loops (EC2 and EC3), which 
comprise a total of nine N-linked glycan residues. The commonly used CD133/1 
and CD133/2 epitopes are located on the EC3 region of CD133 and have the 
potential for epitope masking or antibody inaccessibility due to changes in 
glycosylation patterns. 
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The physiologic function of CD133 in normal biology and the progression of 
cancer remains elusive. CD133 is known to be preferentially localized in plasma 
membrane protrusions and microvilli, suggesting its involvement in membrane 
organization (89, 90). The subcellular localization of CD133 allows it to bind directly 
to cholesterol-containing lipid rafts where it can be involved in various signaling 
cascades (91, 92). Observations from CD133 knockout mice support the 
presumed role of CD133 as a scaffolding protein by showing that a lack of CD133 
caused a defect in outer segment morphogenesis of the photoreceptor cells. While 
these mice remained viable and fertile, they experienced significant retinal 
degeneration and blindness (93). Other studies have additionally suggested a 
potential role of CD133 in determining cellular fate or maintaining stem cell-like 
properties (94-97), however, the precise molecular mechanisms for this are still 
unclear.  
CD133 has primarily been described in the literature as stem cell marker of 
both normal and cancer stem cells (CSCs) in various cancers, including PCa (98-
100). Many different molecular mechanisms have been investigated to better 
understand the modulation of CD133 in both normal and CSCs, but the data is 
highly contradictory. Studies from both normal and CSC lines have indicated that 
CD133 antibody reactivity is reduced when cells are in the G1/G0 portion of the cell 
cycle as opposed to the G2/M phase of the cell cycle, suggesting some level of cell 
cycle dependence related to CD133 expression (101). Hypoxia in the stem cell 
and tumor microenvironment has also been shown to promote CD133 expression 
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via hypoxia inducible factor-1α (HIF-1α) upregulation (102-105). Similarly, a study 
using human glioma cells demonstrated that pharmacologically induced 
mitochondrial dysfunction produced an increase in CD133 protein expression, 
suggesting that hypoxia may also be perturbing the mitochondrial membrane 
potential to regulate CD133 post-transcriptionally (106). It has also been 
suggested that CD133 may play an important role in cellular glucose metabolism 
through modulation of the cytoskeleton (107). In parallel to these roles, a recent 
study also discovered a mechanism by which CD133 inhibited transferrin uptake 
(108). Since transferrin is involved in supplying iron to the cell and iron is required 
for efficient oxygen transport, the CD133-transferrin-iron network may provide a 
potential mechanism for a better understanding of CD133 modulation under 
hypoxic conditions.  
Several reports have also begun to highlight potential signaling pathways 
involved in CD133 expression. The role of CD133 as inductor of Wnt/β-catenin 
signaling has been previously reported in CSCs (109-111). In particular, 
suppression of CD133 was associated with a loss of β-catenin nuclear localization 
and a reduction in canonical Wnt signaling (109, 110). Similar results were also 
reported in normal CD133pos renal cells, suggesting that CD133 may be a 
functional protein and/or a marker of differentiation status (112). Additionally, the 
deacetylase, HDAC6, has been shown to physically interact with CD133 in 
mammalian cells (111). This association stabilized β-catenin, whereas inhibition of 
either CD133 or HDAC6 resulted in increased β-catenin acetylation and 
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degradation and correlated with decreased proliferation and tumorigenesis, 
suggesting another potential role for targeting CD133 for cancer therapy. CD133 
has also been implicated as an important regulator of PI3K/Akt signaling in CSCs 
(113-115), however, due to the complexity of the biological role of CD133, most 
studies focus on its use as a cell surface marker for the detection of somatic stem 
cells and CSCs. The functional role of CD133 is even less clear in the context of 
cancer, as it is ubiquitously expressed in numerous malignant and non-malignant 
tissues (116).  
CD133 in the Healthy Prostate 
In the healthy human prostate, CD133 was first identified as a stem cell 
marker in a rare population (~1%) of basal cells that expressed α2β1 integrin 
(Figure 4). This CD133pos/α2β1high cell population was able to reconstitute prostatic- 
like acini with secretory activity when transplanted into male nude mice, validating 
their stemness and suggesting a hierarchical structure (117). Similarly, CD133 was 
used in combination with other cell surface markers to identify prostate stem cells 
in the proximal region of mouse prostate lobes which also preferentially expressed 
the basal marker CK14, but not the luminal marker CK18 (118). To validate the 
stemness of these cells, single CD133pos/Linneg/Sca-1pos/CD44pos/CD117pos stem 
cell grafts were transplanted into the renal capsule of nude mice and 14 out of 97 
(~14.4%) of the engraftments were capable of prostate development. The above 
studies support the idea that CD133 expression marks a particular basal stem cell 
population by reflecting a hierarchically organized phenotype.  
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Figure 4. Schematic of the different cell types in the prostate and their 
identifying markers. The epithelial compartment is composed of three basic 
cell types: basal, luminal, and neuroendocrine cells; and two intermediate 
phenotypes. Basal cells are non-secretory cells located along the basement 
membrane of the epithelium and are characterized by the following markers: 
ΔNp63 (119), CK5 and CK14 (120, 121), CD44 (122), integrin α2β1 (117), 
integrin α6β1 (123, 124), CD133 (117), CD117 (118), Sca-1 (118, 125), CD49f, 
and Trop2 (126). Basal cells give rise to secretory luminal cells by transitioning 
through intermediate states. Two intermediate phenotypes have been described: 
(1) transit-amplifying cells which are non-secretory and exhibit a more basal-like 
phenotype and (2) intermediate cells which are secretory and exhibit a more 
luminal-like phenotype. Both, transit-amplifying and intermediate cell types may 
express CK5 and CK8, however, only transit-amplifying cells have been shown 
to express CD24 to distinguish them from low-differentiated basal cells (127) and 
only intermediate cells have been shown to express CK19 to distinguish them 
from luminal cells (128). Luminal cells are secretory columnar cells that express 
high AR, CK8 and CK18, and PAP (129). Neuroendocrine cells are very rare 
cells located in the luminal layer and represent less than 1% of the prostatic 
epithelium. They are non-secretory, differentiated cells that express CHGA, 
CD56, synaptophysin, calcitonin, and NSE (130, 131). This figure has been 
adapted from diagrams in related literature (132-134).  
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This hypothesis was supported and accepted for many years, however, 
more recent findings have indicated the presence of CD133 in luminal epithelial 
cells in both human and rodent models (135-137). A study documented that 
CD133pos and CD133neg cells contributed equally to prostate epithelial 
homeostasis, bringing into question the accuracy of CD133 as a true stem cell 
marker (138). Based on the evidence in the prostate alone, it appears to be clear  
that not all CD133pos cells are stem cells and that some CD133neg cells may also 
possess stem-like properties. Several additional studies support this hypothesis by 
demonstrating that CD133 was expressed in differentiated epithelial cells in a 
variety of other organs including the pancreas (139, 140), liver (141, 142), colon 
(116, 143), sweat glands (144), salivary and lacrimal glands (144, 145), uterus 
(144), and kidneys (146). Altogether, these studies indicate that the overall 
expression of human CD133 expands beyond stem cell populations and although 
it appears to negatively correlate with cell differentiation, it is likely not a regulator 
of stemness in most tissues (143). Rather, it is more likely that CD133 is a general 
marker of the apical or apico-lateral membrane of the glandular epithelium (144, 
147). Furthermore, it is important to note that no stem cell population from any 
tissue type has been isolated to clonal purity on the basis of CD133 alone.  
CD133 in Prostate Cancer  
CD133 was first investigated as a PCa stem cell marker using the same cell 
surface markers for identifying normal stem cells in the prostate. One study 
identified PCa stem cells by isolating a population of cells from 40 patient biopsies 
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which was CD44pos/α2β1high/CD133pos (148). This particular cell population was 
postulated to be a CSC population based on its ability to self-renew, proliferate 
extensively, and invade in vitro. The CD44pos/α2β1high/CD133pos exhibited a self-
renewal capacity that was 3.7-fold greater than the CD133neg population. 
Additionally, CD133pos cells from primary and metastatic prostate tumors showed 
increased proliferative potential and invasiveness compared to CD133pos cells 
derived from benign prostate tissues. CD133 has also been used to identify CSCs 
in PCa cell lines though the isolated CD133pos cells regenerate phenotypically 
heterogeneous populations. For example, a CWR22Rv1 culture propagated from 
freshly sorted CD133pos cells (>98%) revealed that only 6.15% of cells remained 
CD133pos after two weeks in culture (149).  
Based on the evidence of rare CD133 expression in somatic stem cells of 
the prostate, it was hypothesized that these CD133pos CSCs populations resulted 
from mutated normal stem cells and thus were derived from basal cells. Several 
early studies supported this theory by showing that the CD133pos cell populations 
exhibited known basal cell identifiers summarized in Figure 4, although the most 
frequently recognized of these basal cell markers is often negative androgen 
receptor expression (ARneg). In these studies, the CD133pos cells had the ability to 
proliferate and differentiate into ARpos cell populations, reflecting the relevance of 
CD133 to a hierarchically organized phenotype.  However, another study 
demonstrated that isolated CD133pos PCa cells were ARpos and exhibited 
significant growth inhibition when exposed to high-dose androgens, suggesting 
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that these CD133pos CSCs may be derived from a malignantly transformed 
intermediate cell rather than normal basal stem cells (149).    
Conversely, some studies have indicated that CD133pos and CD133neg cell 
populations from immortalized primary human PCa tissues demonstrated similar 
tumorigenicity when inoculated into NOD/SCID mice and that the CD133neg cells 
generated significantly more prostaspheres in vitro (150). Thus far, CD133pos CSC 
populations have only been shown to represent roughly 1-5% of the total cell 
population in PCa cell lines (149). However, it has been suggested that CD133pos 
populations could be enriched in vitro through chemotherapy or radiotherapy, 
postulating that these cells exhibit at least some level of chemo/radioresistance 
(151). A study evaluating the circulating tumor cells from 12 metastatic CRPC 
patients established that the CD133pos cells exhibited higher proliferative potential 
than their CD133neg counterparts in 10/12 patients (152), suggesting that CD133pos 
cells do have enhanced potential for cell division despite chemo/radiotherapy. Due 
to the inconsistent evidence supporting CD133 as a PCa stem cell marker, it is still 
unclear whether CD133 plays a direct role in PCa stem cell maintenance or if it is 
simply correlated to more aggressive disease. 
  
27 
 
Goals of Research  
 Tumor heterogeneity is a hallmark of AVPC lesions and a well-documented 
clinical challenge in developing new and improved theranostic agents. Recent 
studies have focused on incorporating a precision medicine-based approach to 
detecting and treating PCa by using specific imaging and therapeutic agents that 
are targeted to the patient based on their tumor pathology. PSMA-targeted 
theranostics have laid the foundation for the development of targeted agents for 
the detection and treatment of specific phenotypes of PCa, but they are limited in 
their ability to target PSMAneg lesions, which are frequently found in the lethal 
AVPC stage of PCa progression. As such, new targetable biomarkers are urgently 
needed to continue improving the diagnosis, disease monitoring, and therapeutic 
options for lethal AVPC.  
 Recent studies on CD133 have indicated that it may play a role in the 
progression of PCa as it is often identified in more aggressive stages of the disease 
which also happen to display higher levels of chemo/radioresistance. To date, the 
investigation of CD133 as a stem cell and CSC marker has dominated the CD133 
literature, but the verdict is still out as to whether CD133 plays a true role in the 
stemness of the cell population. The focus of this dissertation is to investigate 
CD133 as a biomarker of aggressive PCa and develop a novel antibody to 
detect CD133 in preclinical PCa models.   
 Due to the limitations of previously commercialized antibodies binding to 
inaccessible or glycosylated epitopes of CD133, Chapter II focuses on the 
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identification of a novel single chain variable fragment (scFv), termed HA10, which 
detects a glycosylation independent epitope of CD133. In addition to the validation 
of HA10, this chapter also includes a case study describing CD133 expression 
during PCa progression and suggests the significance of targeting CD133 in lethal 
AVPC patients. In Chapter III, CD133 expression in a particular AVPC phenotype 
is defined using a high-throughput analysis. Furthermore, HA10 is converted into 
a full-length IgG, termed HA10 IgG, and used to image preclinical models of PCa. 
Chapter IV concludes my research by elucidating the impact of targeting CD133 
as a biomarker in AVPC and discussing the future directions of this research.    
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CHAPTER II: Development and 
Characterization of a Novel anti-CD133 
Single Chain Variable Fragment (scFv) 
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Introduction 
PCa is a prevalent disease that afflicts men in the western world greater 
than any other malignancy. The inability of therapies to eliminate PCa in a subset 
of patients and the recurrence of disease many years post-radical prostatectomy 
is indicative of the existence of cancer stem/initiating cells. In the healthy prostate, 
a subset of slow-growing ARneg basal cells possess an unlimited ability to self-
renew and differentiate into neuroendocrine cells and transit-amplifying cells that 
ultimately yield the AR-expressing secretory cells that populate the majority of the 
glandular epithelium (153). One model suggests that cancer stem/initiating cells 
arise from these normal stem cells within the basal layer of the prostate epithelium 
after they have accrued mutations that promote carcinogenesis 
(154). Complicating the study of stem cells is their low abundance in the 
heterogeneous prostate epithelium. The pentaspan transmembrane protein, 
CD133, has been used extensively as a marker to identify and isolate prostate 
stem cells and cancer/stem initiating cells (99, 100, 155). Possessing an 
extracellular N-terminal domain (EC1), two large heavily glycosylated extracellular 
loops (EC2 and EC3), and often existing as different splice variants, the biological 
function of CD133 is unknown (84, 156). Identified originally as an antigen present 
on the surface of hematopoietic stem cells in 1997 (157, 158), the expression of 
CD133 has been documented in normal and CSCs from a number of diverse tissue 
and cancer types (100, 117). Underscoring its association with stem cells in the 
prostate, basal cells isolated from benign prostate tissue that expressed α2β1 
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integrin and CD133 were able to regenerate a fully differentiated prostate 
epithelium in vivo (117). Additionally, purported PCa stem cells expressing a 
CD133pos/α2β1high/CD44pos phenotype were isolated from human tumor biopsies 
and demonstrated tumorigenic properties (159).  
Investigating the functional role CD133 plays in the development of the adult 
prostate and in the initiation and progression of cancer is hindered by several 
factors. Very few cell lines uniformly express endogenous CD133. PCa cell lines 
and non-immortalized prostate epithelial cells do possess a minor population of 
CD133-expressing cells (~1–5%) (149). When the CD133pos cells are isolated and 
expanded in culture, CD133 expression is lost returning to the original minor 
population (155). Reliable antibodies for the detection and isolation of CD133 also 
do not exist—this has been a significant limitation in investigating the biology of 
CD133 (85, 160). The two most commonly used antibodies for the isolation and 
analysis of CD133, AC133 (epitope CD133/1) and AC141 (epitope CD133/2), both 
recognize glycosylated epitopes (155). During the lifetime of a protein, 
glycosylation motifs can be pared or lost altogether making them inconsistent 
epitopes for analysis (85, 161). Several investigators have documented that the 
AC133 epitope disappears upon CSC differentiation even though CD133 protein 
and mRNA are still present (83, 162, 163). Further illustrating the paucity of high-
quality antibodies for CD133, studies have found discordant CD133 expression by 
IHC using different CD133 antibodies tested in sections of the same tissues (85, 
160, 164). The dynamic nature of the glycosylation motifs on the extracellular 
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domains of CD133 coupled with the lack of a sensitive antibody suggest that 
CD133-expressing cell populations may be more abundant than previously 
imagined in tissues, but those cell populations are not detectable by the current 
CD133 antibodies. 
In this study, we detailed the characterization of a novel antibody for CD133 
that was identified from a human antibody phage display library. Our antibody, 
termed HA10, was found to bind to a glycosylation-independent epitope on the 
protein backbone of CD133. Using our antibody, we were able to detect CD133 
expression in cell lines by flow cytometry and in formalin fixed paraffin embedded 
tissue sections. In several instances, HA10 was able to detect CD133 expression 
that was not identified by the commercially available AC133 antibody. In 
concordance with previous studies, little CD133 expression in healthy prostate and 
prostate adenocarcinoma sections was observed. We did, however, make a novel 
finding documenting extensive CD133 expression in ARneg LuCaP patient-derived 
xenograft (PDX) models and in a liver biopsy from a patient with ARneg that also 
expressed the neuroendocrine marker, CHGA. 
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Materials & Methods 
Cell Culture  
All cancer cells lines used in this study were purchased from American Type 
Culture Collection (ATCC) except for the CWR-R1CD133 cells which were a 
generous gift from Dr. Donald Vander Griend, University of Chicago (165). Cells 
were maintained in their respective recommended media, supplemented with 10% 
FBS (Gibco), 1% antibiotic-antimycotic (Gibco), and 1% glutaMAX (Gibco) at 37°C 
and 5% CO2. Additionally, enzalutamide resistant (EnzR) cell lines were 
supplemented with 10 μM enzalutamide (APExBIO) at all times. The cell lines were 
authenticated using short-tandem repeat profiling provided by the vendor and 
routinely monitored for mycoplasma contamination. The PC3CD133 knock-in cell line 
was generated using PROM1 Lentifect Purified Lentiviral Particles (LPP-M0038-
Lv105–200-S, GeneCopoeia). PC3 cells were seeded at 5 × 104 cells/well in a 24-
well plate using heat-inactivated FBS. Once cells became 70–80% confluent, 
transduction was performed according to the manufacturers protocol using 7 
μg/mL Polybrene (H9268–5G, Sigma-Aldrich) and 10 μL of lentivirus for 24 h. 
Following overnight incubation, transduced cells were reseeded into three wells of 
a six-well plate and incubated for 48 h. Transduced clones were stably selected 
with 3 μg/mL puromycin for the duration of culture. 
Phage Display Biopanning  
A fully human naïve scFv phage display library was used to identify clones 
against native human CD133. Recombinant human CD133 (NBP2-59787PEP, 
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R&D Systems) was biotinylated using EZ-link™ NHS-PEG4-Biotin (Thermo Fisher) 
at a 20-fold mM excess of biotin to protein. The biotinylated CD133 was captured 
using Dynabeads™ M-270 Streptavidin (Invitrogen) in 100 ng/μL of 1% BSA in 
PBS (137 mM NaCl, 2.7 mM KCl, Na2HPO4, 10 mM, KH2PO4 2 mM pH 7.4) with 
constant inversion for 30 min. The scFv phage display biopanning protocol was 
carried out as previously described in Kim et al. (166). The biopanning protocol 
was repeated three times to enrich for positive binders to glycosylated recombinant 
CD133 and one additional round with deglycosylated CD133. 
Quantitative RT-PCR 
RNA was prepared from each cell line (~2 × 106 cells) using an RNeasy kit 
(Qiagen). RNA was synthesized to cDNA using the High Capacity RNA-to-cDNA 
kit (Applied Biosystems). For each gene, Taqman qRT-PCR was performed using 
the Taqman Universal PCR Master Mix (Applied Biosystems) and the following 
Taqman Gene Expression Assay probes: CD133-Hs01009257_m1 PROM1 for 
experimental samples and 18s ribosomal 1 (reference gene) Hs03928985_g1 
RN18S1 for a normalization control. All qPCR was performed on a StepOnePlus 
Real-Time PCR system instrument (Applied Biosystems). Each reaction was 
performed in triplicate and the data were analyzed using the comparative Ct 
method (fold change = 2−ΔΔCt) as previously described by Schmittgen et al. (167). 
All data are presented as mean ± SEM. 
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ELISA 
ScFvs were produced from 288 individual clones using 5 mM IPTG 
induction in a microtiter plate format. The scFvs that leaked into the cell culture 
media were screened for binding to native and deglycosylated CD133 by ELISA. 
Deglycosylation of CD133 was accomplished using PNGase F (Promega) 
according to the manufacturer’s protocol. MaxiSorp® plates (Nunc) were coated 
with 50 μL of 5 μg/mL of captured CD133 (some experiments used deglycosylated 
or truncated forms of CD133) in 1% BSA in PBS overnight at 4°C. The unbound 
CD133 was removed and wells were washed three times with PBS and blocked 
with 2% BSA in PBS for 1 h at room temperature. The wells were washed three 
times with PBS and the supernatants of scFv induced cultures were added to each 
well and incubated at room temperature for 1 h. The wells were washed three times 
with PBS and the scFv was detected with anti-HA antibody conjugated to 
peroxidase (Roche) in 1% BSA in PBS and Turbo TMB reagent (Pierce). Reactions 
were stopped with 15 μL of 2.5 M H2SO4 and the absorbance was measured at 
450 nm using a microplate reader. Confirmed positive clones for CD133, 
irrespective of glycosylation status, were sequenced to identify unique clones. 
ScFv Expression and Purification  
Unique clones were inserted into pET-22b(+) vectors (Novagen) according 
to the manufacturer’s protocol. Expression of each clone was carried out in 
SHuffle® T7 Competent Escherichia coli K12 cells (NEB). A single colony from 
each clone was selected and cultured overnight at 37°C in 5 mL of 2xYT broth 
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containing 100 μg/mL ampicillin. The 5 mL overnight cultures were used to 
inoculate 1 L cultures of 2xYT broth containing 100 μg/mL ampicillin. Cells were 
cultured at 30°C until the OD600 reached 0.5–0.7. Protein expression was induced 
by the addition of 1 mM IPTG and 0.4 M sucrose and cultured for an additional 16–
18 h at 25°C. Cells were harvested by centrifugation at 6000g for 10 min and the 
periplasmic E. coli fraction was extracted via osmotic shock. Harvested cell pellets 
from each liter of culture were resuspended in 20 mL of 1× TES (0.2 M Tris, pH 8, 
0.5 mM EDTA, 0.5 M sucrose) and 20 mL of 1× EDTA-free protease inhibitor 
(Pierce) solution. Each cell suspension was incubated for 30 min on ice with 
agitation every 10 min. Cells were centrifuged and the supernatant was collected 
as periplasmic fraction 1. This protocol was repeated to the cell pellet to obtain 
periplasmic fraction 2. The two periplasmic fractions were combined and 1 M 
MgCl2 (200 μL) and 5 M imidazole (600 μL) were added prior to purification. The 
periplasmic fractions were filtered through a 0.45 μm filter and purified by 
Ni2+ affinity chromatography as follows. A 5-mL HisTrap HP column (GE 
Healthcare) was equilibrated with 20 mM NaPO4, 0.5 M NaCl, 40 mM imidazole, 
pH 7.4. The clarified periplasmic fraction was loaded onto the column and washed 
with equilibration buffer for 10 column volumes and bound protein was eluted with 
20 mM NaPO4, 0.5 M NaCl, 500 mM imidazole, pH 7.4 Eluted scFvs were 
collected, concentrated using a 10 kDa centrifugal filter, and buffer exchanged into 
D-PBS using a Sephadex G-25 PD-10 desalting column (GE Healthcare). Each 
scFv was subject to analysis by reducing and non-reducing SDS-PAGE and 
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protein concentrations were measured based on absorbance at 280 nm using a 
NanoDrop™ One UV-Vis Spectrophotometer (Thermo Fisher). 
IgG Production  
The heavy chain and light chain variable domains of the HA10 sequence 
were cloned separately into pFUSE2ss derived rabbit IgG expression vectors 
(invivogen) and co-transfected into HEK293T (Life Technologies) cells for 72 h. 
Following incubation, the serum was collected, filtered through a 0.45 μm filter, 
and purified using a 1 mL HiTrap Protein A HP column (GE Healthcare). The 
column was equilibrated with 20 mM sodium phosphate, pH 7.4. The serum was 
loaded onto the column and washed with equilibration buffer for 10 column 
volumes and bound protein was eluted with 0.1 M citric acid, pH 3. Eluted IgGs 
were collected, concentrated using a 50 kDa centrifugal filter, and buffer 
exchanged into D-PBS, and analyzed as described above. 
Surface Plasmon Resonance 
SPR measurements were obtained using a BIAcore T100 instrument. The 
native recombinant CD133 protein was captured on a CM5 sensor chip by amine 
coupling at pH 4.5 to a final immobilization density of ~680 resonance units (RU). 
Un-reacted sites were blocked with 1M ethanolamine. A control flow cell without 
immobilized CD133 protein was prepared for reference subtraction. Dilutions of 
HA10 in running buffer (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, pH 7.4 
[HBS-T] or 50 mM phosphate, 100 mM NaCl, 0.01% Tween 20, pH 6) were injected 
over the chip for 200 s followed by a 600 s dissociation in running buffer. The chip 
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was regenerated with a 30 s injection of 10 mM glycine, pH 2.5, and two 45 s 
injections of HBS-T. The flow rate used for all methods was 30 L/min. Binding 
affinities were derived by analysis of the generated sensograms using the Biacore 
T100 evaluation software. The equilibrium RU observed for each injection was 
plotted against protein concentration and fit to a steady-state affinity model 
included in the evaluation software for determination of the equilibrium binding 
affinity (KD). 
ScFv-Fluorphore Conjugation 
A total of 0.5 mg of HA10 was labeled with a 3-fold molar excess of Alexa 
Fluor® 488-NHS ester (Life Technologies) dissolved in DMSO under alkaline 
conditions (pH 9.0) using 1 M sodium bicarbonate. The conjugation reaction was 
performed for 90 min at room temperature with gentle agitation. Unbound Alexa 
Fluor® 488 was removed by performing a buffer exchange into D-PBS using a 
Sephadex G-25 PD-10 desalting column (GE Healthcare). Labeled HA10 was 
concentrated using a 10 kDa centrifugal filter and the protein concentration and 
degree of labeling were determined as follows: 
Protein concentration (M) = [(A280 – (A494 x 0.11)) x dilution factor] / [Molar 
extinction coefficient (M)] 
Moles dye per mole protein = [A494 x dilution factor] / [71,000 x protein 
concentration (M)] 
39 
 
Flow Cytometry 
Cells were harvested by incubation with TrypLE for 3 min at 37°C. 1 × 106 
cells were labeled with either 1 μM HA10, 0.1 mg/mL of commercialized CD133/1 
(AC133, #130–105-226) purchased from Miltenyi Biotec, or 0.1 mg/mL of an IgG 
control (#130–092-213, Miltenyi Biotec) for 30 min at 4°C. Cells were washed two 
times and resuspended in flow cytometry staining buffer (eBioscience). Cell 
samples were analyzed on a FACSCalibur flow cytometer (Becton-Dickinson) and 
at least 10,000 viable cells were gated and analyzed with FlowJo software. 
Immunoprecipitation 
Cell lysates were prepared using non-denaturing 1% triton X-100 lysis 
buffer with protease and phosphatase inhibitors. The concentrations of cell lysates 
were determined using an RCDC assay. Purified HA10 (2 μg) was incubated with 
0.5 mg of cell lysate overnight at 4°C to facilitate antibody conjugation. Protein A/G 
Plus-Agarose beads (#sc-2003, Santa Cruz Biotechnology) were added to the 
lysate-antibody mixture and incubated for 3 h at 4°C. The immunoprecipitant was 
washed three times with D-PBS and captured proteins were eluted using 40 μL of 
1× laemmli buffer. The sample was boiled at 95°C for 5 min and centrifuged at 
100×g for 5 min to remove majority of the agarose beads from the precipitant. The 
eluate was analyzed by SDS-PAGE followed by subsequent western blotting using 
the commercialized AC133 antibody (Miltenyi Biotec) as well as mass 
spectrometry using a Linear Ion Trap mass spectrometer (Thermo Scientific) and 
PEAKS proteomics software package. 
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Immunohistochemistry 
The LuCaP tissue microarray (TMA) was acquired from the Prostate Cancer 
Biorepository Network (PCBN). The LuCaP TMA was constructed with each PDX 
model in triplicate. Patient biopsies for analysis were acquired using a University 
of Minnesota Human Subjects Division approved Institutional Review Board (IRB) 
protocol for tissue acquisition (IRB#1604M86269) and with patient consent. The 
healthy prostate tissue and adenocarcinoma TMAs were obtained from the 
BioNET Tissue Procurement Facility at the University of Minnesota. The samples 
for these TMAs were all arranged in duplicate. The patient samples for the TMA 
were originally acquired using an approved IRB protocol for tissue procurement. 
Unstained sections (4 μm) were de-paraffinized and rehydrated using standard 
methods. For antigen retrieval, slides were incubated in 6.0 pH buffer (Reveal 
Decloaking reagent, Biocare Medical) in a steamer for 30 min at 95–98°C, followed 
by a 20 min cool down period. Endogenous peroxidase activity was quenched by 
slide immersion in 3% hydrogen peroxide solution (Peroxidazed, Biocare Medical) 
for 10 min followed by TBST rinse. A serum-free blocking solution (Sniper, Biocare 
Medical) was placed on sections for 30 min. Blocking solution was removed and 
slides were incubated in primary antibody diluted in 10% blocking solution/90% 
TBST. The following primary antibodies and concentrations used were: CD133 
HA10 antibody, rabbit monoclonal (1:100); androgen receptor SP107 (Sigma), 
rabbit monoclonal (1:200); chromogranin A PB9097 (Boster Biological 
Technology) rabbit polyclonal (1:1000); CD133/1 (AC133) (Miltenyi) mouse 
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monoclonal (1:25). Slides were rinsed in TBST buffer followed by detection with 
Novalink polymer (Leica Biosystems) according to manufacturer’s directions. All 
slides then proceeded with TBST rinse and detection with diaminobenzidine (DAB) 
(Covance). Slides were incubated for 5 min followed by TBS rinse then 
counterstained with Harris Hematoxylin for 1 min. Slides were then dehydrated and 
cover slipped. An independent pathologist reviewed the stained slides and 
assigned a qualitative staining intensity score of negative, weak, moderate, and 
strong. The staining patterns were described as rare (0–25% cells positive), 
variable (25–75% positive), and uniform (>75% positive). 
Statistical Analysis 
A one-way ANOVA using GraphPad Prism 7 was used to calculate statistics 
for PROM1 mRNA expression from qRT-PCR experiments. Each cell line was 
compared to the calibrator (PPT2) to determine statistically significant levels of 
CD133 mRNA expression. All other assays were carried out 2–3 times and data 
replication were observed in repeated experiments. 
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Results 
Antibody Identification  
A human scFv antibody phage display library with a diversity of 8 × 109 was 
initially screened for three rounds against glycosylated recombinant CD133. 
Biopanning was performed using biotinylated CD133 attached to magnetic 
streptavidin coated beads to ensure that the protein retained some three-
dimensional structure. An additional round of biopanning was performed with 
CD133 that had been deglycosylated by PNGase F treatment to enrich for clones 
against a glycosylation-independent epitope. After the fourth round, 288 
independent clones were screened by ELISA using fully glycosylated CD133. Of 
those clones, 122 showed high ELISA signals and 14 clones cross-reacted with 
deglycosylated CD133. Sequence analysis of the 14 clones discovered 8 unique 
antibodies. One scFv, designated HA10, expressed well in E. coli (~2 mg/L) and 
was selected for further characterization studies. After purification, the majority of 
the purified product was composed of scFv, however, some dimerized and 
oligomerized products were also present (Figure 5A), which is in accordance with 
previously documented scFv preparations (168, 169).  Subsequent SPR analysis 
determined that the monovalent HA10 scFv possessed a KD of 3 nM for fully 
glycosylated CD133 (Figure 5B). Additionally, the epitope of HA10 was found to 
reside on the extracellular domain 2 (EC2) of CD133 by ELISA using recombinant 
biotinylated fragments of each extracellular domain (Figure 5C). In contrast, both 
of the commercially available antibodies, AC133 and AC141, are known to bind to 
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Figure 5. Validation of HA10 binding to CD133. A) SDS-PAGE gel of purified 
HA10 scFv displays some dimer and oligomer formation. B) SPR measurements 
of immobilized CD133 interacting with 3, 6, 25, 50, 200, and 400 nM of purified 
HA10 are shown, demonstrating potent binding to native recombinant CD133 
with a KD = 3 nM C) ELISA assay of HA10 with purified recombinant CD133 
extracellular loops (EC2 and EC3) shows that HA10 binds to an epitope located 
on the EC2 domain of CD133. Detection of HA10 binding was performed using a 
peroxidase conjugated HA-tag antibody and Turbo TMB reagent. 
OD450 measurements were obtained on a microplate reader and a control blank 
well containing no immobilized protein was used to assess background 
absorbance D) To further confirm the binding of HA10 to CD133, CD133 was 
immunoprecipitated from two CD133pos cell lines, CWR-R1CD133 and CaCo2 
(colon cancer) using HA10. Western blot analysis with the Miltenyi Biotec 
CD133/1 (AC133) antibody and mass spectrometry of the immunoprecipitant 
were used to confirm the identity of CD133. IP, immunoprecipitant; SN, 
supernatant; W, pooled washes. 
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glycosylated epitopes on the extracellular domain 3 (EC3). Immunoprecipitation 
with HA10 revealed binding to CD133 in the colon cancer cell line, CaCo2; and the 
PCa cell line, CWR-R1CD133 which was engineered to express CD133 (Figure 5D). 
Lentiviral transduced and naturally expressing CD133pos cell lines were next 
analyzed by flow cytometry and western blot to compare the binding of HA10 scFv 
to the AC133 antibody which targets the CD133/1 epitope on EC3. First, CD133 
gene expression analysis was used to evaluate mRNA levels of PROM1, which 
encodes for CD133.  The artificially expressing cell lines, PC3CD133 and CWR-
R1CD133, displayed significantly higher levels of PROM1 compared to the remaining 
cell lines. Additionally, the naturally expressing cell lines: E006AA-hT, E006AA-
hT-EnzR, PPT2, and CaCo2 showed 100-1000-fold more PROM1 compared to 
the CD133neg cell lines (Figure 6A). Despite the high mRNA levels in the artificially 
expressing cell lines, flow cytometry and western blotting revealed that CD133 
protein expression was similar to the colon cancer cell line, CaCo2, which serves 
as a positive control (Figures 6B and 6C). As seen by the negligible shift in the 
histograms, insignificant staining was only observed in the CD133neg parental PC3 
and CWR-R1 cells, confirming the lack of cross-reactivity of HA10 with other 
human proteins. Conversely, PC3CD133 and CWR-R1CD133 cell lines were 
specifically labeled by both HA10 and AC133 at almost equivalent levels. Both 
antibodies were next tested with the naturally expressing CaCo2 cell line and the 
recently identified CD133pos PCa cell line, PPT2 (170). HA10 showed comparable 
staining in CaCo2 cells and stained 21.5% more of the PPT2 cell population than 
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Figure 6. Analysis of CD133 expression in various cell lines. A) High levels of 
PROM1 mRNA expression were observed in the artificially (p<0.0001) expressing PCa 
cell lines. Despite being insignificant, total PROM1 mRNA expression in the naturally-
expressing cell lines were comparable to the positive control, CaCo2, whereas CD133 
mRNA expression levels in the CD133neg prostate cancer cell lines were roughly 0.001–
0.1% of the remaining cell lines when analyzed by qRT-PCR. B) Flow cytometry was 
used to compare the specificity and staining intensity of HA10 (purple line) and the 
Miltenyi antibody CD133/1 (AC133) (black line) on these various CD133-expressing live 
cells. Both antibodies were compared to an unstained control (red line) to identify any 
non-specific binding. Staining profiles on the negative and transduced cell lines suggest 
comparable performance, however, higher staining profiles were observed in naturally 
expressing cell lines with HA10 compared to the AC133 antibody. C) Comparable 
detection was observed in all cell lines by western blot.  
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AC133. Additionally, since African Americans are known to exhibit more 
aggressive PCa, the African American PCa cell lines, E006AA-hT and E006AA-
hT-EnzR, were assessed for CD133 expression. Similar to the PPT2 cells, staining 
was only observed with HA10 in a small population of cells, while AC133 was 
unable to detect CD133 expression on the cell surface (Figure 6B). When the same 
cell lines were analyzed by western blot, the antibodies were comparable in signal 
across all cell lines (Figure 6C). Interestingly, there is a small population of 
E006AA-hT-EnzR cells identified using HA10 in the flow cytometry analysis that is 
not detected via western blot, which may be due to changes in structure or epitope 
alterations from the lysis procedure. However, these results ultimately suggest that 
HA10 may be more effective at detecting CD133 in naturally expressing CD133pos 
cell populations, potentially due to the effects of CD133 glycosylation, epitope 
masking, or protein truncation. 
Antibody Staining in Fixed Tissues 
The variable heavy and light chains of HA10 scFv were cloned into rabbit 
IgG scaffold vectors for expression in a mammalian system. After purification, the 
rabbit IgG version of HA10 was used by IHC to detect CD133 in formalin-fixed 
paraffin embedded sections from subcutaneous CWR-R1CD133 and PC3CD133 
xenografts. HA10 detected strong uniform of CD133 with >75% of the cancer cells 
stained in the transduced models with no appreciable staining observed in the 
parental sections as anticipated (Figures 7A-7D). Mock tissue sections of PC3CD133 
cells embedded in paraffin also demonstrated specific staining for CD133  
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Figure 7. IHC validation of HA10. Staining with HA10 is depicted in FFPE 
xenograft sections derived from parental cell lines and cell lines 
engineered to express CD133. No immunoreactivity was present in a parental 
R1 section (A) but was in the engineered R1CD133 section (B). Staining was not 
observed in a parental PC3 section (C) while strong uniform staining was in the 
PC3CD133 section (D). Mock tissue sections of the PC3 cells were made consisting 
of fixed cells embedded in paraffin and then sectioned (E and F). CD133 was 
absent in PC3 parental cell mock tissue section (E). The mock tissue section of 
the PC3CD133 cells did show positive staining (F). Scale bar, 60 μm. 
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compared to the non-transduced control cells (Figures 7E and 7F). After the IHC 
protocol was optimized, a panel of healthy human tissues were stained with HA10 
to assess CD133 distribution (Figure 8). Staining was largely absent in healthy 
human tissues, except for weak and variable staining in colon. The presence of 
CD133 in the colon and in colon cancer has been documented before (171). 
Tissue microarrays of healthy prostate tissue and adenocarcinoma 
(Gleason 6–9) were next analyzed for CD133 expression using HA10. 
Immunoreactivity was found in very few of the healthy and diseased sections. Out 
of the 150 healthy prostate sections, the presence of CD133 was observed in only 
12 sections (8%). All of the CD133 was located in the prostate epithelium with no 
detectable staining in the stroma (Figure 9). Positivity was greatest on the apical 
side of luminal cells. Staining was not uniform across luminal cells, however, with 
cells adjacent to CD133pos cells often showing no immunoreactivity (Figure 9A). 
Basal cell staining was only observed in one healthy prostate section (Figure 9B) 
while another section displayed complex epithelial staining that may have included 
basal cells (Figure 9C). CD133 immunoreactivity was almost equally as sparse in 
the prostate adenocarcinoma sections with only 10 out of 110 (9%) sections 
demonstrating immunoreactivity (Figure 9D). The staining was confined to the 
apical side of luminal cells with no basal staining observed in the sections that were 
surveyed. The presence of CD133 in the adenocarcinoma sections did not 
correlate with Gleason Grade, PSA level, or progression free survival.  
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Figure 8. HA10 staining in healthy tissue. A) kidney, B) liver, C) spleen, D) 
lung, E) illium, F) small intestine, G) placenta, H) ovaries and I) skin. Scale bar, 
200µm. 
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Figure 9. CD133 staining in the healthy prostate and prostate 
adenocarcinoma using HA10. The presence of CD133pos cells was rare in 
healthy tissue with 12/150 (8%) of the sections displaying immunoreactivity (A-
C). A) Non-uniform staining of luminal cells was present in the glandular 
epithelium of a healthy prostate. B) A collection of basal cells in the glandular 
epithelium demonstrating the presence of CD133. C) An example of complex 
epithelial staining in a healthy prostate section. D) CD133 staining of luminal 
cells in an adenocarcinoma section Gleason 4 + 3. Only 10/110 (9%) of the 
adenocarcinoma sections had detectable CD133 present. Scale bars, 200 μm 
for the wide view and 60 μm for the magnification. 
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In order to more fully interrogate the potential expression of CD133 in 
heterogeneous primary and metastatic PCa, we stained a TMA constructed of the 
LuCaP PDX models (Figure 10). Out of the 42 LuCaP PDX models, only three 
(LuCaP 49, 145.1, and 145.2) were immunoreactive resulting in a uniform staining 
pattern akin to the engineered PC3CD133 and CWR-R1CD133 xenografts. No staining 
was detected in any of the LuCaP sections using an optimized protocol for the 
commercially available AC133 antibody. The CD133pos LuCaP models were all 
ARneg and express at least one marker of neuroendocrine differentiation (CHGA or 
synaptophysin), as did their originating tumors. We did not observe any CD133 
positivity in sections of the other ARneg LuCaP model with neuroendocrine 
differentiation features, LuCaP 93. 
Clinical Case Study of CD133 Expression  
A liver biopsy was obtained from a PCa patient who underwent treatment 
at the University of Minnesota Masonic Cancer Center. The patient was originally 
diagnosed with aggressive PCa (Gleason 4 + 5, T3bN1M0, PSA of 45 ng/mL) and 
underwent a transurethral resection of the prostate (TURP). Shortly afterwards, a 
CT scan of the abdomen and pelvis showed bilateral pelvic lymphadenopathy and 
ADT consisting of lueprolide and bicalutamide was initiated. After 1 year of ADT, 
the patient’s PSA had dropped to 2.8 ng/mL. Progression on ADT was observed 
after 25 months of treatment by an increase in PSA to 87 ng/mL and the 
development of extensive skeletal metastases. The patient then started on 
treatment with abiraterone and prednisone. After a year on this regimen, his PSA  
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Figure 10. CD133 expression in LuCaP PDX models using HA10 and the 
Miltenyi antibody CD133/1 (AC133). None of the LuCaP PDX models were 
found to be positive for CD133 using the AC133 antibody. The neuroendocrine 
prostate cancer-derived models LuCaP 49 and LuCaP 145.1 did show staining 
for CD133 using HA10. Staining with HA10 was not observed in any of the other 
LuCaP PDX models, including AR positive LuCaP 73 shown at the lower right. 
Each image is representative of three replicates for each model. No variability 
was observed between the replicates. Scale bar, 100 μm. 
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had decreased from 87 to 17 ng/mL, however, a CT scan found extensive liver 
metastasis (Figure 11A). Biopsies of the liver lesions were found to be positive for 
CD133 based on staining with HA10 (Figure 11B). Strong CD133 staining was 
largely uniform across the tumor foci standing in stark contrast to the apical 
staining pattern observed in the healthy prostate and adenocarcinoma sections. 
Subsequent IHC analysis found that the liver metastases were also negative for 
AR expression (Figure 11C) and positive for the neuroendocrine marker, CHGA 
(Figure 11D). A TURP section from this patient stained with HA10 found no CD133 
expression in the original primary disease (Figure 11E). The patient initially 
responded well to chemotherapy with carboplatin and taxotere, but progressed 
rapidly after 8 months developing extensive visceral metastases in the presence 
of declining PSA. A liver biopsy acquired after resistance to carboplatin and 
taxotere occurred was subsequently found to be positive for CD133 demonstrating 
moderate staining intensity with >50% of the tumor cells positive (Figure 11F). No 
sections from this patient were stained with AC133 due to scarcity of the samples.   
  
54 
 
 
  
 
Figure 11. Case study of a patient with aggressive prostate cancer. A) CT 
scan of diffuse liver metastases that appeared in the presence of declining PSA 
after the patient failed treatment with Zytiga (abiraterone). B) Strong staining for 
CD133 was detected in the liver metastases using HA10. C) No staining for the 
AR was observed in the liver metastases using an antibody specific to the N-
terminal domain of the AR. This antibody would detect both full-length AR and 
AR splice variants. D) Staining was observed for the neuroendocrine 
differentiation marker, CHGA, in the liver metastases. E) An original TURP 
specimen from the patient depicting poorly differentiated Gleason 4 + 5 cancer 
stained for CD133. Note the complete absence of CD133. F) Liver biopsy from 
the patient after failing treatment with carboplatin and taxotere documenting 
moderate staining for CD133. Scale bars, (B-D) 200 μm and (E-F) 60 μm. 
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Discussion  
For many years, hybridoma technology has been the preferred method for 
identifying monoclonal antibodies against target antigens (172). This technology 
has allowed for the discovery of thousands of monoclonal antibodies that are used 
as laboratory reagents, nuclear imaging probes, and antibody-based therapeutics 
in the clinic. Though it has been successful, there are several limitations of 
hybridoma technology. Recent studies have suggested that less than a quarter of 
all commercially available antibodies actually bind to their target antigen or work 
for their intended application (173, 174). Hybridoma-derived antibodies often 
cannot distinguish between highly homologous members of the same protein 
family or proteins with significant posttranslational modifications such as 
glycosylation (175). Antibody phage display is a powerful technique that can 
rapidly identify recombinant monoclonal antibodies for challenging targets where 
traditional hybridoma technology has failed. Since it is an in vitro technology, the 
selection process in antibody phage display can be modified to enrich for highly 
unique clones that bind to specific epitopes. Here, we used antibody phage display 
to select for an antibody fragment that bound to a glycosylation-independent 
epitope on the protein backbone of CD133. The unique antibody discovered 
through this selection process, HA10, was able to detect CD133 in cell lines and 
fixed tissues.  
Since its discovery in the late 1990s, CD133 has been viewed as a marker 
for stem cells of the healthy prostate as well as cancer (117, 155). The isolation 
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and analysis of CD133 expressing cells has primarily been conducted using the 
AC133 antibody. It is has been established that the AC133 epitope, but not CD133 
protein, is lost when stem cells differentiate (83). Splice variants of CD133 are also 
known to exist that could potentially affect the epitopes used for detection (176). 
Based on this evidence, it is plausible that the AC133 epitope represents a 
population of CD133 that is only found in undifferentiated stem cells. As the basal 
stem cells in the prostate differentiate into transit-amplifying cells and ultimately 
luminal cells, the AC133 epitope is lost, but CD133 variants with de novo epitopes 
are present in the progeny. These new CD133 populations cannot be detected by 
AC133 or AC141, but can by antibodies, such as HA10, that recognize non-
glycosylated epitopes that are consistently exposed on non-truncated protein 
domains. This hypothesis could potentially explain our flow cytometry data and the 
staining patterns that were observed by IHC.  
By flow cytometry, both HA10 and AC133 bound to immortalized cancer cell 
lines that were engineered to artificially express full-length CD133. In the 
endogenously expressing CaCo-2 and PPT2 cells, HA10 recognized a greater 
population of positive cells than AC133. CaCo-2 cells differentiate and lose the 
AC133 epitope upon continuous coculturing suggesting that the cells used for flow 
cytometry had several CD133 epitope populations that could only be detected by 
HA10. The same can be argued for PPT2, which is a recently discovered PCa 
stem cell line that can form three-dimensional spheroids over prolonged passages. 
Most interestingly, only HA10 was able to detect CD133 on the surface of E006AA-
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hT cells. E006AA-hT is a subline of E006AA, a cell line that was originally isolated 
from a primary Gleason 3 + 3 tumor of an African-American patient (177, 178). 
These cells possess hallmarks of terminally differentiated luminal cells that have 
undergone oncogenic transformation such as AR expression. Based on these 
findings, it is possible to say that E006AA-hT cells harbor several CD133 epitope 
populations, none of which display the AC133 epitope. 
Previous IHC studies using the AC133 antibody discovered that CD133 was 
a marker for a truly rare basal cell type with less than 1% of all basal cells staining 
positive for CD133 (117). No report has ever documented the staining of luminal 
epithelial cells with AC133 in the prostate. Another antibody for CD133, 80B258, 
which recognized an epitope on the polypeptide backbone, was immunoreactive 
with basal cells and the apical side of luminal cells (137). Our findings with HA10 
align with the 80B258 data and not AC133. Basal cell staining was observed with 
HA10 and was indeed found to be quite rare since only one section out of 150 was 
unequivocally positive. HA10 also reacted with luminal epithelial cells, staining the 
apical side of those cells. In contrast to other antibodies, however, HA10 also 
stained epithelial cells distant from the lumen and closer to the basement 
membrane. This pattern of staining was not observed with 80B258 and has never 
been documented before for CD133 in the prostate. The same group that analyzed 
80B258 staining in healthy prostate tissues found no immunoreactivity in 
adenocarcinoma sections. With HA10, we did observe weak staining in 
adenocarcinoma sections, but it too was extremely rare. 
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CD133 expression in the LuCaP TMA further highlighted the differences 
between AC133 and HA10. Immunoreactivity was not observed with AC133 in any 
of the models, but CD133 expression was detected by HA10 in three models. The 
three positive LuCaP models were all originally derived from metastatic ARneg 
neuroendocrine PCa with LuCaP 145.1 and LuCaP 145.2 originating from the 
same patient. A fourth neuroendocrine model that was derived from a TURP 
specimen, LuCaP 93, was not positive for CD133. Using HA10, we were also able 
to detect CD133 in liver biopsies of a patient who failed second-generation anti-
androgen therapy with abiraterone. As with the CD133pos LuCaP models, the 
metastatic lesions from this patient displayed neuroendocrine differentiation based 
on the expression of CHGA. It is not possible to arrive at any formal conclusions 
about the biology of CD133 based on our findings with the LuCaP TMA and patient 
biopsy, except that its biology appears to be complex. The AC133 epitope was not 
present in the LuCaP models and staining with HA10 in the liver biopsies was 
strong and uniform in contrast to healthy prostate and adenocarcinoma sections. 
It appears that lack of an AR by itself does not necessarily correlate with CD133 
expression and other factors are involved with the induction of CD133. To illustrate 
this point, both DU145 and PC3 are ARneg yet only possess a minor population of 
CD133pos cells similar to that of LNCaP. E006AA-hT cells express both CD133 and 
AR, though the AR of this cell line has an S599G mutation that renders it inactive 
and the cells indifferent to castrate levels of androgen (179). The absence of 
CD133 in the original TURP specimen of the patient suggests that the CD133 in 
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the liver biopsies may originate from divergent clonal evolution, but it is difficult to 
say since biopsies at multiple stages of the disease were not taken (180). In order 
to come to any conclusion about the expression of CD133 in ARneg cancer with 
neuroendocrine differentiation, more samples from a number of metastatic sites 
need to be analyzed. 
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CHAPTER III: Exploitation of CD133 for the 
Targeted Imaging of Lethal Prostate Cancer   
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Introduction  
The management of patients with metastatic PCa initially relies on inhibiting 
the AR signaling axis by ADT through surgical castration or gonadotropin-releasing 
hormone agonists. The therapeutic benefit of ADT is transient and patients 
inevitably develop disease recurrence, also known as CRPC, which can occur as 
early as 18 months after the initiation of ADT (181-183). Driven by aberrant AR 
signaling, second-generation anti-androgens have had a profound effect in 
extending the lifespan of patients with CRPC (183). Unfortunately, many patients 
present with de novo resistance to these therapies and those that receive an initial 
benefit often develop acquired resistance quite rapidly through mechanisms such 
as AR amplification, mutation, and splice variant expression. Similarly, many men 
with de novo or acquired resistance to AR-signaling inhibitors may display a non-
AR driven form of disease referred to as AVPC (182, 184, 185). AVPC broadly 
encompasses CRPC that is non-AR driven and may express neuroendocrine 
markers or possess small cell morphology (22, 186-188). This lethal subset of PCa 
is characterized by high metastatic burden in both the bone and viscera, minimal 
response to therapy, and poor overall prognosis (21, 23). 
Effective treatment options for AVPC currently do not exist and novel 
therapies are urgently needed. Critical to the development of novel therapies for 
AVPC is the ability to accurately image this disease in patients. For decades now, 
bone scintigraphy using 99mTc methylene diphosphonate (99mTc-MDP) has been 
considered the most cost-effective and accurate imaging modality for metastatic 
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PCa patients despite its limited sensitivity and specificity for cancerous lesions (42, 
47). Furthermore, recent studies using the PET tracer, NaF, have demonstrated 
superior sensitivity for detecting bone lesions in PCa patients (37, 42). While this 
is successful for the majority of AVPC patients who present with bone metastases, 
a striking 20% also present with visceral disease, rendering bone scintigraphy and 
NaF-PET imaging inadequate (189, 190). Other PET imaging agents, such as 11C-
acetate, 11C/18F-choline, and 18F-fluciclovine, have been employed to image PCa 
biochemical recurrence (37, 58, 60, 191), however, these agents have yet to be 
investigated for AVPC. Recently, there has been much success imaging PSMA in 
bone and visceral metastases of patients with prostate adenocarcinoma using 
small molecule PET radioligand probes (76). Several PSMA imaging studies have 
documented a lack of probe uptake in ARneg metastatic lesions suggesting that 
AVPC does not express PSMA (180, 192, 193). As such, there is currently no 
accurate imaging modality available for AVPC patients.    
The lack of targetable antigens specific to AVPC has complicated the 
development of an imaging agent for this disease subtype. The heavily 
glycosylated pentaspan transmembrane protein, CD133, has often been described 
as an antigen on the surface of both stem cells and CSCs (98). In a previous study, 
we used human antibody phage display to identify a novel antibody for CD133, 
termed HA10 (194). Herein, we show that CD133 is highly overexpressed at the 
mRNA and protein level in a multitude of patients possessing AVPC with an ARneg, 
neuroendocrine marker-positive (AR-/NE+) phenotype. By microarray analysis, we 
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confirmed that CD133 and PSMA expression were inversely related and that 
AVPC is PSMAneg. Moreover, we used a full-length human IgG version of HA10 to 
selectivity identify CD133pos cancer cells by near-infrared (NIR) optical and 89Zr-
PET imaging in subcutaneous tumor and metastatic mouse models of AVPC. Our 
findings identified CD133 as a novel, previously unknown marker of AR-/NE+ 
AVPC that can be exploited as an imaging target to assess and monitor disease 
progression. Additionally, CD133-targeted imaging agents could aid in the 
development of novel therapeutics for a subtype of PCa that is currently incurable 
by monitoring patient response to therapy.     
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Materials & Methods 
Cell Culture 
HEK293T cells were purchased from the ATCC and were maintained 
according to ATCC guidelines. CWR-R1 cells and luciferase-expressing CWR-R1-
EnzR cells were obtained from Dr. Scott Dehm (Masonic Cancer Center, University 
of Minnesota) and Dr. Donald Vander Griend (Department of Pathology/Surgery, 
University of Illinois at Chicago), respectively. All parental cell lines were 
authenticated by short tandem repeat profiling prior to manipulation. Parental 
CWR-R1 and CWR-R1-EnzR cells were lentivirally transduced to express CD133 
as previously described (194). Expression of CD133 in transduced cell lines 
(CWR-R1CD133 and CWR-R1-EnzRCD133) was confirmed via qPCR and western 
blot and compared to CD133neg parental cell lines. All cells were grown in DMEM 
supplemented with 10% fetal bovine serum, 1% antibiotic-antimycotic, and 1% 
glutamax and incubated at 37°C and 5% CO2. Additionally, CD133 expressing 
cells were continuously supplemented with 3 µg/mL puromycin to ensure stable 
levels of CD133 expression.    
Antibody Production 
The protocols for biopanning, ELISA screening, scFv expression and 
purification, as well as affinity/specificity characterization of the isolated scFv 
clone, HA10, were followed as previously described (194). The heavy chain (354 
bp) and light chain (318 bp) variable domains of the HA10 sequence were cloned 
separately into pFUSE2ss derived human IgG expression vectors (InvivoGen) and 
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co‐transfected into HEK293T cells according to manufacturer’s guidelines. 
Following incubation, the serum was collected, filtered through a 0.45-µm filter, 
and purified using a 1 mL HiTrap Protein A HP column (GE Healthcare). The 
column was equilibrated with 20 mM sodium phosphate, pH 7.4 prior to loading the 
serum sample. The column was washed with equilibration buffer for 20 column 
volumes and bound protein was eluted with 0.1 M citric acid, pH 3. The eluate was 
collected and concentrated using a 50-kDa centrifugal filter. A final buffer 
exchange was performed into 1x PBS using a Sephadex G‐25 PD‐10 desalting 
column (GE Healthcare). The purity of the final HA10 human IgG was analyzed by 
reduced and non‐reduced SDS‐PAGE and the concentration was measured based 
on absorbance at 280 nm using a NanoDrop™ One UV‐Vis Spectrophotometer 
(Thermo Fisher). 
DNA Microarray 
PCa patient tissue samples were obtained from patients who died of 
metastatic CRPC and who signed written informed consent for a rapid autopsy 
performed within 6 hours of death as part of the Prostate Cancer Donor Program 
at the University of Washington. A total of 171 tumors from 63 patients were 
collected for profiling by expression microarray using the protocol previously 
described in Kumar et al. (195). LuCaP xenografts were also profiled using the 
same protocol. 
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Immunohistochemistry 
Curated samples for analysis were obtained from the PCBN and the 
University of Minnesota Masonic Cancer Center using a University of Minnesota 
Human Subjects Division approved IRB protocol for tissue acquisition 
(IRB#1604M86269) and with patient consent. The tissue sections were stained for 
CD133 using a previously described procedure (194). A pathologist reviewed the 
slides and assigned IHC scores as previously reported (196). The AR-/CHGA+ 
(n=25) soft-tissue metastases were liver (n=14), lymph node (n=3), lung (n=2), 
retroperitoneal (n=4) and pleural (n=2) while the AR+/CHGA adenocarcinoma 
sections (n=10) were liver (n=6), lymph node (n=2) and lung (n=2).  
Fluorescent Microscopy  
CWR-R1-EnzR and CWR-R1-EnzRCD133 were seeded on borosilicate 
coverglass slides (Nunc) and grown to 50% confluence. An internalization staining 
protocol was used to determine whether the HA10 IgG exhibited cellular uptake. 
The living cells were first treated with 1 µM of HA10 IgG in 1% bovine serum 
albumin (BSA) in 1x PBS for 15 m at 37°C. Following primary antibody removal, 
the cells were washed twice with 1xPBS, fixed with 4% paraformaldehyde for 10 
m at room temperature, washed twice with 0.2 M glycine (pH 2.4), permeabilized 
with 0.25% Triton X-100 for 15 m at 37°C, and washed twice with 1x PBS prior to 
secondary antibody application. The fixed cells were treated with 10 µg/mL of 
Alexa Fluor 488-labeled goat anti-human IgG (Invitrogen) in 1% BSA in 1x PBS for 
30 m at 37°C. After removal of the secondary antibody, the cells were washed 
67 
 
twice, counterstained with 0.3 µM DAPI, and washed two more times prior to 
analysis via confocal microscopy (Olympus).  
Animal Models 
All animal studies were performed in athymic nu/nu mice (Envigo) following 
Institutional Animal Care and Use Committee (IACUC) approval at the University 
of Minnesota. For subcutaneous tumor implantation, animals (n=3-4/group) 
received unilateral injections on the right shoulder of 1x106 CWR-R1 or CWR-
R1CD133 cells (in 100 µL) in a 1:1 dilution of Matrigel (Corning) to 1x PBS. Tumors 
were measured twice weekly with calipers and volumes were calculated as length 
x width x height. For the intracardiac dissemination model, animals (n=4/group) 
received injections of 2x105 CWR-R1-EnzR or CWR-R1-EnzRCD133 cells (in 100 
µL) in 1x PBS directly into the left ventricle of the heart, with a 75% accuracy rate. 
Following the intracardiac injections, mice were weighed twice/week to assess 
overall health and bioluminescent imaging was performed once/week to evaluate 
tumor formation and growth. 
In Vivo Fluorescent Imaging  
HA10 IgG was labeled with IRDye 800CW NHS Ester (LI-COR Biosciences) 
according to the manufacturer’s instructions to develop a near-infrared (NIR) 
imaging agent (NIR-HA10 IgG). Mice bearing subcutaneous tumors were imaged 
when all tumors in each group reached a threshold of 100 mm3. Each mouse was 
administered 1 nmol (155 µg) of NIR-HA10 IgG via tail vein and imaged at 1, 5, 
24, 48, 72, 96, 120, and 144 h post-injection. Following intracardiac dissemination, 
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mice exhibiting sizeable metastatic lesions as indicated by bioluminescent imaging 
(BLI) were administered 1 nmol (155 µg) of NIR-HA10 IgG via tail vein and imaged 
at 24, 48, 72, and 144 h. In both studies, animals were imaged using an IVIS 
Spectrum scanner (Perkin Elmer) and euthanized at a fixed endpoint 6 days after 
the NIR-HA10 IgG injection or monitored for overall health and terminated when 
tumor volumes reached 1,000 mm3 or weight decreased more than 15%. To 
determine fluorescent intensity of subcutaneous xenografts, manually drawn 
regions-of-interest (ROIs) were normalized to a background level of fluorescence 
on each mouse. To account for variability in size and luciferase expression of 
intracardiac tumors, a relative radiance unit was determined by dividing the total 
radiant efficiency of the NIR imaging by the total counts of the BLI signal and used 
to quantify differences in signal between CD133pos and CD133neg mice. 
Bioconjugation and Radiochemistry  
For nuclear imaging studies, HA10 IgG was conjugated to p-SCN-Bn-
Deferoxamine (DFO, Macrocyclic) as previously described (197). Zirconium-89 
(89Zr) was produced and purchased from the University of Wisconsin Medical 
Physics Department. Once received, 89Zr-oxalate (7.5 mCi) in 1.0 M oxalic acid 
(600 μL) was adjusted to pH 6.8–7.5 with 1.0 M Na2CO3. To radiolabel the IgG, 
the DFO-HA10 IgG conjugate (400 µL, 3.49 mg/ml, 1.4 mg of mAb) in 0.5 M 
HEPES (pH 7.5) was added to the neutralized 89Zr-oxalate solution and incubated 
at room temperature with gentle agitation for 1 h. The labeled product was purified 
using a PD-10 column pre-equilibrated with PBS buffer. Crude and purified 
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samples were analyzed by radio-TLC using 50 mM EDTA (pH 5.0) as the eluent. 
The specific activity of 89Zr-HA10 IgG was calculated to be 2.3 mCi/mg and the 
radiochemical purity was >98%. 
Immunoreactivity  
The immunoreactivity of 89Zr-HA10 IgG was assessed by using antigen-
specific cellular binding assays using the CD133-transduced cell line (CWR-R1-
EnzRCD133) and the non-CD133 expressing parental cell line (CWR-R1-EnzR). 
CWR-R1-EnzR and CWR-R1-EnzRCD133 cells were suspended in micro-
centrifuge tubes at concentrations of 0.5, 1, 2, 3, 4, and 5 x 106 cells/mL in 500 µL 
of 1x PBS. Aliquots of 89Zr-HA10 IgG (50 µL, 25 µCi) in 1% bovine serum albumin 
were added to each cell suspension (final volume 550 µL) and incubated at room 
temperature with gentle agitation for 1 h. Cells were resuspended and washed 
twice with ice-cold 1x PBS. The supernatant was removed and the 89Zr 
radioactivity of the cell pellets were counted using a HIDEX automatic gamma 
counter (HIDEX, Finland). The count data was background corrected and the 
immunoreactive fraction of 89Zr-HA10 IgG was assessed by comparing the total 
number of counts in the cell suspensions by control samples.  
Stability Studies 
The stability of 89Zr-HA10 IgG with respect to change in radiochemical purity 
was evaluated at 0, 48, 96, and 144 h following purification. For the stability 
studies, 35 µCi of 89Zr-HA10 IgG was added to 500 µL of 1% BSA in 1x PBS and 
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incubated at room temperature. The radiochemical purity of 5 µL of 89Zr-HA10 IgG 
was assessed at each time point by radio-TLC. 
In Vivo PET/CT Imaging  
PET imaging experiments were conducted on an Inveon µPET/CT scanner 
(Siemens Medical Solutions). Mice were administered 89Zr-HA10 IgG formulations 
(150-200 μCi, 25-30 μg of mAb, in 200 μL of 1x PBS) via tail vein injection.  
Approximately 5 minutes prior to recording PET/CT images, mice were 
anesthetized by inhalation of 2% isoflurane and placed in the scanner bed in the 
prone position. PET images were recorded at various time-points between 24–144 
h post-injection. PET list-mode data were acquired for 30 min using a γ-ray energy 
window of 350–650 keV and a coincidence timing window of 3.438 ns. CT 
acquisition was performed for 5 mins at 80 kVp, 500 µA, 384 ms per step, and 340 
steps covering 220 degrees. CT images were reconstructed using a Hu scaled 
Feldkamp algorithm resulting in 192 × 192 matrix and PET utilized Ordered Subset 
Expectation Maximization (OSEM-3D) with 18 subsets and 2 iterations resulting in 
a 128 × 128 matrix. 2D images were prepared in Inveon Research Workplace and 
quantified using AMIDE. An empirically determined system calibration factor was 
used to convert voxel count rates to activity concentrations and the resulting image 
data were normalized to the administered activity to parameterize images in terms 
of %ID/g. Manually drawn ellipsoid ROIs were used to determine the mean %ID/g 
in various tumors. 
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Statistical Analysis 
All statistical analyses were performed using Graphpad 7.04. Quantitative 
RT-PCR and luciferase assay experiments prior to xenograft implantation were 
repeated three times with three technical replicates each time; all results were 
represented as mean ± SEM. IHC scores were compared using a Mann-Whitney 
t-test to account for differences in sample size. Patient microarray data was 
analyzed using a one-way ANOVA which was corrected for multiple comparisons 
using Sidak hypothesis testing and LuCaP microarray data was analyzed using a 
Welch t-test. Pearson's correlation coefficient was used to study the relationships 
between the genes shown in scatterplots. Animal studies were performed with 
n=3-4 and signals intensities were quantified as mean ± SEM in bar charts or mean 
± min/max in box plots. Statistical significance was determined using a two-way 
ANOVA and corrected for multiple comparisons using Sidak hypothesis testing. 
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Results 
CD133 is overexpressed in AR-/NE+ PCa 
Our initial studies on CD133 suggested an inverse relationship between AR 
and CD133 expression in a limited number of samples by immunohistochemistry 
(194). To assess whether CD133 mRNA overexpression was associated with a 
particular PCa phenotype, 171 tumor samples resected from 63 rapid autopsy 
subjects were analyzed for CD133 expression as well as gene signatures which 
demonstrate the AR status and NE differentiation of each tumor sample (Figure 
12A) (180, 186, 195). The gene that encodes CD133, PROM1, displayed the 
highest level of expression in AR-/NE+ tissues (p<0.0001, Figure 12B). CD133 and 
AR expression exhibited a moderate inverse correlation (Pearson correlation = -
0.5989, Figure 12C). Similarly, expression of the prototypical AR related genes, 
FOLH1 and KLK3, which encode for PSMA and PSA respectively, were also 
inversely correlated to CD133 expression (Pearson correlation=-0.5042, Figure 
12D; Pearson correlation=-0.4789, Figure 12E).  
Since early passages of PDX models display similar morphology to the 
original tumors from which they are derived (198), 24 early-passage LuCaP 
xenografts were investigated for expression of CD133. Only four PDX models 
displayed an AR-/NE+ gene signature and three (75%) of these models showed 
overexpression of PROM1 (Figure 13A), which was statistically significant when 
compared to the AR+/NE- PDX models (p<0.0001, Figure 13B). Complimentary to 
the gene expression in patient samples, CD133 exhibited a very strong inverse  
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Figure 12.  Gene signatures demonstrate that CD133 is overexpressed in 
an AR-/NE+ PCa phenotype in patient tissue samples. A) CD133 (PROM1) 
expression was evaluated across PCa tumors that displayed gene signatures 
signifying AR and NE status. B) CD133 expression in PCa patient samples was 
significantly increased in AR-/NE+ AVPC patients compared to other subtypes. 
C) Graph documenting a negative overall correlation between CD133 and AR 
expression in patient tumors. D) A negative overall correlation was also observed 
between CD133 and PSMA expression in patient tumors, and E) there was a 
negative overall correlation between CD133 and PSA expression (Pearson 
correlation, r=-0.4789) in patient tumors.  
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Figure 13.  Gene signatures demonstrate that CD133 is overexpressed in 
an AR-/NE+ PCa phenotype in PDX models. A) CD133 expression was 
evaluated across 24 LuCaP PDX models. B) Quantification of CD133 expression 
in LuCaP PDX models was significantly increased in AR-/NE+ samples 
compared to AR+/NE- xenografts. C) A negative overall correlation was 
identified between CD133 and AR expression in the LuCaP PDX models. D) 
There was a negative overall correlation between CD133 and PSA expression 
(Pearson correlation, r=-0.8565) in LuCaP PDX models.  
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correlation to both AR and KLK3 in the PDX models (Pearson correlation=-0.886, 
Figure 13C; Pearson correlation=-0.8565, Figure 13D).       
Having elucidated the relationship between AR status, NE differentiation 
and CD133 at the mRNA level, we next used immunohistochemistry to investigate 
CD133 protein expression in soft-tissue metastases. Patient tissues (n=35) were 
classified as either adenocarcinoma (n=10) when sections were AR+/CHGA- or 
neuroendocrine AVPC (n=25) when sections were AR-/CHGA+. All of the 
adenocarcinoma tissue sections were negative when stained for CD133 (Figure 
14A). Contrarily, 92% (23/25) of the neuroendocrine AVPC tissue sections 
displayed intense staining and the remaining 8% (2/25) displayed moderate 
staining for CD133 (Figure 14B). Scoring of the staining intensity in all samples 
revealed that CD133 expression was significantly different between 
adenocarcinoma and neuroendocrine AVPC patients (p<0.0001, Figure 14C). 
Detecting CD133 in vivo by near-infrared optical imaging  
In the study described in Chapter II, we identified a human scFv, termed 
HA10, that specifically bound to CD133 expressed on the cell surface by flow 
cytometry (194). HA10 was expressed as a full-length bivalent human IgG (IgG1 
scaffold) and labeled with the NIR fluorophore IRDye 800CW (NIR-HA10 IgG) for 
NIR optical imaging. NIR optical imaging was initially used as a proof-of-concept 
to document the specific localization of the antibody and acquire pharmacokinetic 
properties allowing for the informed selection of the appropriate radioisotope for 
PET imaging. Since no immortalized PCa cells lines uniformly express CD133,  
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Figure 14. Immunohistochemistry shows CD133 overexpression in 
neuroendocrine-differentiated AVPC tissue sections. A) Representative 
images of CD133 expression in adenocarcinoma tissue sections at 200 µm and 
60 µm. B) Representative images of CD133 expression in neuroendocrine-
differentiated tissue sections at 200 µm and 60 µm. C) Quantitative analysis 
showed a significant increase in CD133 staining intensity from adenocarcinoma 
to neuroendocrine-differentiated tissue sections.  
 
  
60 µm 
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model systems were developed as previously described (194). The human PCa 
cells lines CWR-R1 and luciferase-expressing CWR-R1-EnzR were transduced to 
express CD133. CD133 expression in each cell line was quantified by qPCR 
(Figure 15).  
Additionally, cellular uptake assays were performed to assess whether 
HA10 would serve as an ideal imaging probe prior to in vivo studies. For these  
assays, CWR-R1-EnzR and CWR-R1-EnzRCD133 cells were fixed to coverglass 
slides prior to or after HA10 IgG incubation to allow for surface or internalized 
staining, respectively. Cellular uptake was monitored using fluorescent microscopy 
(Figure 16). Both staining protocols revealed high fluorescent signals in the 
CD133pos cells upon imaging. In contrast, no signal was observed in the CD133neg 
cells in either protocol. Moreover, the different staining protocols demonstrated that 
HA10 IgG binds to the cell membrane and is internalized in the CD133pos cells.  
Mice bearing either subcutaneous CWR-R1 (n=4) or CWR-R1CD133 (n=4) 
tumors were administered 1 nmol of NIR-HA10 IgG via tail vein and imaged at 1, 
5, 24, 48, 72, 96, 120, and 144 h. As early as 24 h post-injection of NIR-HA10 IgG, 
increased uptake in the CD133pos CWR-R1CD133 tumors was observed compared 
to the CD133neg tumors (Figure17A). Localization of the antibody to CD133pos 
tumor remained present up to 144h. A small amount of non-specific localization 
due to the enhanced permeability retention effect was observed in the CWR-R1 
tumors, however, the antibody cleared by 72 h post-injection. Similar EPR effects 
have been observed with the PSMA-targeted antibody and it is still considered   
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Figure 15. Confirmation of CD133 in cells prior to xenograft implantation. 
A) CD133 is artificially overexpressed in transduced CWR-R1 cells, and B) 
CD133 is artificially overexpressed in transduced luciferase-expressing CWR-
R1-EnzR cells.  
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Figure 16. CD133 is internalized into CD133-expressing cells. An 
internalization staining protocol revealed cellular uptake of HA10 into CD133pos 
CWR-R1-EnzR PCa cells. For the internalized staining protocol, both cell lines 
were treated with 1 µM of HA10 IgG for 15 minutes prior to fixation. For the 
surface staining protocol, both cell lines were treated with 1 µM of HA10 IgG for 
15 minutes after fixation. Fixed cells were incubated with an Alexa Fluor 488-
labeled anti-human IgG (green) and counterstained with DAPI.            
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Figure 17. NIR-HA10 IgG is selective for CD133-positive subcutaneous 
tumors. A) NIR imaging of mice bearing either CD133-positive (CWR-R1CD133) 
or CD133-negative (CWR-R1) subcutaneous tumors. Mice received 1 nmol of 
NIR-HA10 IgG via tail vein and then were imaged serially at the designated 
times. B) Quantitative analysis of the subcutaneous tumors from the NIR optical 
imaging experiment displayed significantly higher signals between 24-72 h post-
injection. Values represent mean ± SEM of 4 animals/group. C) Ex vivo IHC 
(40X) and NIR image of representative mouse tumors at 144 h post-injection of 
NIR-HA10 IgG. Values represent mean ± SEM of 3-4 animals/group. 
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specific enough for clinical translation as a theranostic agent (199). Average 
fluorescent intensity in CD133pos tumors remained significantly higher than 
CD133neg tumors from 24 to 72h (Figure 17B). After the final 144 h time point, the 
tumors were excised from the mice, imaged by NIR and stained for CD133 
expression (Figure 17C). The CWR-R1CD133 tumors displayed high levels of 
CD133 expression across the entire tumor by IHC, indicating stable CD133 
expression following xenograft implantation, while immunoreactivity was absent in 
the CWR-R1 tumor sections. Similarly, NIR imaging demonstrated a strong signal 
in the CWR-R1CD133 tumors which was not present in the CWR-R1 tumors, 
verifying that the NIR-HA10 IgG was retained by the tumor and able to selectively 
detect CD133 up to 144h post-injection.   
The ability of NIR-HA10 IgG to detect small, dispersed CD133-postive 
lesions in complex microenvironments was next tested in a metastasis model. To  
create an appropriate spontaneous metastasis model, mice received intracardiac 
injections of either luciferase-expressing CWR-R1-EnzR (n=4) or luciferase-
expressing CWR-R1-EnzRCD133 (n=3) cells. The luciferase activity of the cells was 
assessed 1-3 days prior to injection in all mouse models (Figure 18A). 
Bioluminescent imaging was performed on the mice once per week to assess 
lesion formation and size. Once mice in each group had at least one sizeable tumor 
 (>3x105 total counts), they received 1 nmol of NIR-HA10 IgG via tail vein.  NIR 
optical imaging was then conducted at 24, 48, 72, and 144 h post-injection (Figure 
18B). Comparable to the subcutaneous model, the signal was highly visible and  
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Figure 18. NIR-HA10 IgG is selective for CD133-positive metastatic tumors. 
A) Verification of luciferase expression in CWR-R1-EnzR derived cell lines. B) 
NIR imaging of representative mice possessing either CD133-positive (CWR-
R1-EnzRCD133) or CD133-negative (CWR-R1-EnzR) metastatic tumors. Mice 
received 1 nmol of NIR-HA10 IgG via tail vein and then were images at the 
designated times. C) Quantitative analysis of metastatic tumors from mice used 
in D displayed a significantly higher signal at 48 h post-injection. Values 
represent mean ± SEM of 3-4 animals/group. 
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specific for CD133pos tumors at 24 h, remained high for up to 72 h, and was still 
detectable at 144 h. The quantitative analysis supported this observation 
demonstrating a significant difference in relative radiance at 48 h (p=0.0383) and 
a noticeable decline in signal between 72 and 144 h in CD133pos tumors (Figure 
18C). Furthermore, the relative radiance signal remained low in the all of the 
CD133neg tumors with minimal tumor or mouse variability, suggesting that the NIR-
HA10 IgG is highly selective for CD133 pos tumors. 
PET/CT imaging of CD133 
The results of the NIR optical imaging studies suggested that longitudinal 
PET imaging studies could be possible using radiolabeled HA10 IgG. Therefore, 
we decided to use the long-lived positron emitting radioisotope 89Zr (t1/2 - 3.3 d) for 
PET imaging. Additionally, PET imaging with 89Zr-DFO conjugated antibodies, 
including studies with the PSMA-targeted antibody J591, are commonplace in the 
clinic (199-202). HA10 IgG was first conjugated to DFO and radiolabeled with 89Zr-
oxalate at room temperature under slightly alkaline conditions using modified 
methods from Zeglis et al. (197). Purity was assessed by radio-TLC and peaks 
were compared to a pure 89Zr4+ standard (Figure 19A). Only 89Zr-HA10 IgG sample 
preparations which resulted in a purity of >98% and a specific activity of >2mCi/mg 
were used for future analyses. 
The stability of 89Zr-HA10 IgG was determined by radio-TLC after incubation 
in 1% BSA in PBS for up to 144 h at room temperature (Figure 19B). The 
radiochemical purity remained above 96% at all the time points, indicating a <2%  
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Figure 19. Characterization of 89Zr-HA10 IgG. A) A representative radio-TLC 
chromatogram of a sample preparation including un-conjugated 89Zr4+ standard, 
crude 89Zr-HA10 IgG, and pure 89Zr-HA10 IgG. B) Overlayed radio-TLC 
chromatograms of 89Zr-HA10 IgG in 1% BSA in PBS at 0, 48, 96, and 144 h post-
preparation (purity >96% in all samples). C) The immunoreactivity of 89Zr-HA10 
IgG was assessed by using antigen-specific cellular binding assays using 
CD133-positive cells (CWR-R1-EnzRCD133) and CD133-negative cells (CWR-
R1-EnzR). The CD133-positive cell line demonstrated a concentration-
dependent increase in immunoreactive fraction compared to the CD133-
negative cell line, indicating high specificity of 89Zr-HA10 IgG for the CD133 
antigen (p=0.0006). 
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decrease at any given time. Thus, 89Zr-HA10 IgG was expected to remain intact in 
vivo on the time-scale described in our PET imaging studies. Similarly, 
immunoreactivity was measured by an antigen-specific in vitro cellular association 
assay using CWR-R1-EnzR and CWR-R1-EnzRCD133 cells (Figure 19C). The 
immunoreactive fraction of 89Zr-HA10 IgG was directly proportional to the number 
of CD133pos cells in the sample and displayed a strong linear relationship in the 
CD133pos cell line (R2=0.9588). CD133neg control cells showed no binding to 89Zr- 
HA10 IgG (R2=0.0003), further demonstrating the specificity of 89Zr-HA10 IgG for 
CD133-expressing cells. 
The ability of 89Zr-HA10 IgG to detect CD133-postive cancer cells in vivo 
was first tested in mice bearing subcutaneous CWR-R1CD133 (n=3) or parental 
CWR-R1 (n=3) tumors. Mice were injected with 150 µCi (67 µg, 2.22 mCi/mg) via 
tail vein and imaged by µPET/CT at 24, 48, 72, and 144 h (Figure 20A). Transverse 
2D images of the CWR-R1CD133 xenografts showed the highest signals in the tumor 
compared to the CWR-R1 xenografts which showed high liver uptake. Additionally, 
3D reconstructions were generated to assess 89Zr-HA10 IgG uptake across 
multiple planes. Tumor margins were well defined in CWR-R1CD133 images 
between 24 and 72 h, which was not observed in the CD133neg xenografts. Both 
groups of mice displayed nearly complete clearance at 144 h. Time activity curves  
were generated from the PET images to display the mean %ID/g of 89Zr uptake in 
the CD133pos versus CD133neg groups of tumor-bearing mice (Figure 20B). A 
significant difference was observed at the 24 and 48 h time points with mean %ID/g  
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Figure 20. 89Zr-HA10 IgG displays significantly higher tumoral uptake in 
CD133-positive tumors. A)  Reconstructed 3D and 2D PET/CT images of mice 
bearing either CD133-positive (CWR-R1CD133) or CD133-negative (CWR-R1) 
subcutaneous tumors. Mice received 150 µCi of 89Zr-HA10 IgG via tail vein and 
then were imaged at the designated times. B) Quantitative analysis of 
subcutaneous tumors from mice used in A displayed significantly higher signals 
at 24 and 48 h post-injection. Values represent mean ± SEM of 3 animals/group. 
C) Ex vivo biodistribution of 89Zr-HA10 IgG in all tissues of mice bearing 
subcutaneous CWR-R1-EnzRCD133 or CWR-R1-EnzR tumors. Mice were 
injected with 10-15 µCi of 89Zr-HA10 IgG via tail vein prior to sacrifice at the 
designated time points. Values represent mean ± SEM of 3-4 animals. 
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values averaging 28.96 ± 0.92 (CWR-R1CD133) and 18.97 ± 1.56 (CWR-R1) at 24 
h (p=0.0003) and 23.60 ± 2.04 (CWR-R1CD133) and 15.94 ± 1.89 (CWR-R1) at 48 
h (p=0.0041). 
Ex vivo biodistribution was performed to evaluate overall distribution and 
potential off-target effects of 89Zr-HA10 IgG (Figure 21 and Table 3). The data 
reveal that distribution of 89Zr-HA10 IgG was comparable in all organs between the 
two groups, with the exception of the tumors. At 24 h, 89Zr uptake was higher in 
CD133pos tumors at a level which was considered insignificant, but at 72 h the 
average %ID/g of 89Zr uptake was approximately 3-fold higher in CD133pos tumors 
at a level which was considered insignificant, but at 72 h the average %ID/g of 89Zr 
uptake was approximately 3-fold higher in CD133pos tumors (p<0.0001). Similarly, 
minimal 89Zr uptake was observed in various other organs. This data correlates 
well with the PET imaging data and suggests that CD133 is a promising antigen 
that can be selectively targeted for the imaging of CD133-expressing tumors.   
The diagnostic potential of 89Zr-HA10 IgG was further investigated by 
µPET/CT imaging in mice bearing spontaneous metastatic lesions. Following 
intracardiac injection with luciferase expressing CWR-R1-EnzRCD133 or CWR-R1-
EnzR cells, mice underwent bioluminescent imaging once per week to monitor 
spontaneous lesion development and growth. At approximately 3.5 weeks post- 
injection, the remaining healthy CD133pos (n=2) and CD133neg (n=2) mice had 
developed multiple metastatic lesions in or around the bone (Figure 22A). Mice 
were injected with 200 µCi (22 µg, 9.5 mCi/mg) of 89Zr-HA10 IgG via tail vein and 
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Figure 21. Ex vivo biodistribution of 89Zr-HA10 IgG in all tissues of mice 
bearing subcutaneous CWR-R1-EnzRCD133 or CWR-R1-EnzR tumors. Mice 
were injected with 10-15 µCi of 89Zr-HA10 IgG via tail vein prior to sacrifice at 
the designated time points. Values represent mean ± min/max of 3-4 animals. 
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Table 3. Ex vivo biodistribution data. Complete biodistribution of 89Zr-HA10 
IgG administered via tail vein into mice bearing subcutaneous CWR-R1-
EnzRCD133 or CWR-R1-EnzR xenografts. 
 
CWR-R1-EnzRCD133 CWR-R1-EnzR 
Organ  24 h (n=4) 72 h (n=3) 24 h (n=4) 72 h (n=4) 
Blood 8.64 ± 2.39 2.87 ± 1.49 7.64 ± 1.01 2.30 ± 1.47 
Heart 2.87 ± 0.33 1.99 ± 0.12 2.65 ± 0.73 1.87 ± 0.17 
Lung 2.36 ± 0.56 1.26 ± 0.12 2.32 ± 0.92 1.36 ± 0.13 
Liver 5.31 ± 1.39 5.38 ± 0.73 5.63 ± 1.02 6.56 ± 2.27 
Spleen 5.21 ± 2.32 3.97 ± 2.20 7.18 ± 1.57 5.40 ± 2.25 
Intestines 1.91 ± 0.45 1.23 ± 0.40 3.04 ± 0.48 1.45 ± 0.41 
Kidney 2.68 ± 0.55 2.34 ± 0.08 2.74 ± 0.46 2.15 ± 0.30 
Muscle 1.14 ± 0.54 0.96 ± 0.58 1.27 ± 0.20 0.63 ± 0.25 
Bone 2.46 ± 0.14 1.88 ± 0.24 2.44 ± 0.68 2.10 ± 0.32 
Tumor 6.06 ± 2.00 12.74 ± 6.19 4.58 ± 1.25 4.30 ± 0.50 
Tumor/Blood 0.70 ± 0.12 5.56 ± 4.24 0.60 ± 0.13 2.40 ± 1.16 
Tumor/Muscle 5.52 ± 0.64 18.51 ± 16.50 3.60 ± 0.82 7.52 ± 2.96 
*The data are expressed as the mean %ID/g ± SD. The errors for tumor/blood 
and tumor/muscle ratios are calculated as the geometric mean of the standard 
deviations.  
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Figure 22. 89Zr-HA10 IgG can selectively detect CD133-positive metastatic 
PCa tumors by PET/CT imaging. A) PET/CT imaging of representative mice 
bearing either CD133-positive (CWR-R1-EnzRCD133) or CD133-negative (CWR-
R1-EnzR) metastatic tumors. Mice received 200 µCi of 89Zr-HA10 IgG via tail 
vein and then were images at the designated times. B) Quantitative analysis of 
metastatic tumors from mice used in A displayed significantly higher signals at 
72 h post-injection. Values represent mean ± min/max of 4 tumors/group from 2 
animals/group. 
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imaged by µPET/CT at 24 and 72 h. 2D and 3D images revealed a high level of 
89Zr distribution at 24 h in both groups of mice, while 89Zr uptake at 72 h was 
exclusively observed in the tumors of CD133pos mice. Quantification of the mean 
%ID/g of 89Zr uptake in the tumors confirmed these results by showing that there 
was no significant difference at 24 h despite higher signals in the CD133pos tumors, 
27.41 ± 2.50 versus 19.35 ± 2.63 (Figure 22B). At 72 h, the mean %ID/g in the 
tumors was significantly different among the two groups, 24.30 ± 3.19 and 11.82 ± 
0.57, respectively (p=0.0069).  
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Discussion  
The emergence of non-AR driven disease in patients with CRPC has 
steadily increased after the introduction of AR-signaling inhibitors such as 
abiraterone and enzalutamide (181, 186, 203). At this stage of disease, survival is 
poor and therapies that dramatically prolong life do not exist. While new therapies 
are in demand, new imaging agents to monitor disease progression and response 
to therapy are also needed. PSMA-targeted radiotracers that have shown promise 
at detecting bone and visceral metastases in patients with adenocarcinoma are 
ineffective due to the lack of PSMA expression in non-AR driven PCa. As such, 
novel antigens and targeted imaging agents are needed to aid in the detection and 
monitoring of this subtype of disease. In this study, we have identified CD133 as a 
new targetable antigen that is overexpressed in one of these non-PSMA 
expressing patient populations and developed a novel antibody-based imaging 
agent that can accurately detect CD133 in preclinical models of PCa. To our 
knowledge, this is the first study demonstrating that CD133 is a promising marker 
for AR-/NE+ AVPC. Furthermore, despite the use of preclinical CD133-targeted 
PET imaging in other cancers (204), this is the first time that CD133 has been 
targeted for imaging of PCa.  
Our targeted agent, HA10 IgG, showed significant selectivity and sensitivity 
for CD133-expressing tumors using multiple imaging modalities and cancer 
models, verifying the specificity of the antibody-antigen interaction. Interestingly, 
subcutaneous xenograft models in both the NIR and PET imaging studies 
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displayed better tumoral uptake at earlier time points (between 24-48 h, Figure 
17A and 20A), whereas, metastatic xenografts displayed better uptake at slightly 
later time points (between 48-72 h, Figure 18B and 22A). It has been shown that 
different PCa xenografts exhibit varying degrees of vasculature as determined by 
tumor-stromal interaction, size, and site of the tumor (205). Differences in these 
factors are likely to account for the slightly different uptake kinetics exhibited by 
the HA10 IgG. Additionally, PET imaging revealed that 89Zr-HA10 IgG tumoral 
uptake varied within the CD133pos metastatic tumors. While all CD133pos tumors 
were visible at 72 h in the 2D images, only some tumors were visible in the 3D 
reconstruction after background normalization, suggesting there was less 89Zr-
HA10 IgG uptake in some of the metastatic lesions. Due to the high signals in the 
small spinal tumor and large mandibular tumor, we postulated that size and 
anatomical location were not the primary causes of this occurrence. We also 
determined that CD133 expression is stable following implantation of the 
xenografts, however, we did not rule out that the metastatic process and tumor 
microenvironment of the secondary site may have altered the tumor phenotype 
and resulted in less 89Zr-HA10 IgG uptake. Multiple studies have suggested that 
preclinical metastatic models may lack the ability to faithfully mimic the tumor 
microenvironment during metastasis (206-208), which may explain the reduced 
PET signal in some of the CD133pos metastatic lesions.     
In conclusion, this study illustrates the importance of identifying new 
antigens for targeted imaging and treatment monitoring of AVPC patients. Our data 
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show that AVPC patients with an AR-/NE+ phenotype possess high levels of the 
surface protein, CD133. Our previous studies show that the epitope our antibody 
recognizes on CD133 is not highly expressed in early stages of PCa or healthy 
tissues (194), demonstrating its promise as targetable biomarker for late-stage 
AVPC patients. Furthermore, our data show that CD133 can be exploited for 
improved imaging using a novel antibody developed by our lab. HA10 IgG was 
specific for CD133pos tumors by various imaging modalities, including clinically 
relevant modality PET/CT imaging. These encouraging results indicate that 89Zr-
HA10 IgG displays high potential as a radiotracer for non-invasive immunoPET 
imaging of AR-/NE+ AVPC patients.   
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CHAPTER IV: Conclusions and Future 
Directions  
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Conclusions 
CD133 is an unreliable CSC marker in PCa but is likely an effective biomarker for 
a subset of AVPC 
 CD133 has been postulated to identify CSCs in numerous solid cancers 
including brain cancer (209), PCa (148), and colon cancer (210). In many of these 
studies, CD133-expressing CSCs exhibited self-renewal potential and the ability 
to regenerate a histologically similar tumor mass following transplantation into 
immunodeficient mice. However, using CD133 to identify and isolate CSCs has 
recently become controversial for the following reasons: 1) it is frequently identified 
in the glandular epithelium in some tissues which could make it difficult to 
differentiate between CSCs and non-stem like cancer cells, 2) a few studies have 
documented the inability of CD133pos cell populations to recapitulate the original 
tumor morphology when xenotransplanted suggesting that CD133 may also be 
expressed on differentiated cells, and 3) some studies have shown CD133neg 
populations are able to recapitulate the original tumor morphology suggesting that 
CD133 may not uniquely mark CSCs (98). Despite the unreliable nature of CD133 
as a CSC marker, studies in brain, colon, and renal cancer have indicated that 
CD133 overexpression is correlated to shorter patient survival and more 
aggressive disease (211-213), suggesting its role as a biomarker of cancer 
progression rather than stemness directly. This research encompasses the first 
studies to establish and define CD133 as a biomarker of aggressive disease in 
PCa.       
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CD133 is overexpressed in AR-/NE+ AVPC patients 
 The first evidence of CD133 overexpression in PCa patients was identified 
in a case study described in Chapter II. This patient presented with high-risk 
regional PCa and underwent a TURP and ADT therapy which initially caused a 
reduction in PSA, however, the cancer had progressed after 1 year of treatment. 
The patient immediately began second-generation anti-androgen therapy and 
displayed some level of biochemical regression, but also developed clinical 
progression in the form of extensive liver metastases, indicating a shift from AR-
driven CRPC to non-AR driven AVPC. Interestingly, the liver metastases showed 
strong staining for CD133, while the original TURP biopsy exhibited no CD133 
expression. Our studies also revealed that the non-AR expressing liver metastasis 
biopsy displayed high staining for the neuroendocrine marker, CHGA, indicating 
that CD133 may be specific to a particular phenotype of AVPC which is AR-/NE+.  
In Chapter III, we tested this hypothesis using DNA microarrays from 171 
CRPC patient tumor samples. Each sample was evaluated for markers of AR gene 
regulation, neuroendocrine differentiation, and CD133 expression. The gene 
signatures for AR and NE status were chosen according to previously published 
literature. These results revealed that only the AR-/NE+ phenotype of AVPC 
patients exhibited significantly elevated levels of CD133 expression. Similarly, 
these results indicated that there was an inverse relationship between CD133 
expression and PSMA expression in this patient population, suggesting that this is 
a valuable biomarker for patients that do not express PSMA. These data were 
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confirmed by immunohistochemistry of 35 PCa patient tissue samples (25 AR-
/NE+ samples and 10 AR+/NE- samples). All 25 AR-/NE+ patients displayed 
moderate to high staining for CD133, while the 10 AR+/NE- patients showed no 
staining for CD133, concluding that CD133 is a selective biomarker for AR-/NE+ 
AVPC.    
Development of the novel antibody, HA10 IgG, facilitated better CD133 detection 
than commercially available antibodies 
 The most frequently used commercially available antibodies for CD133 bind 
to glycosylated epitopes of the EC3 domain. Since CD133 is known to be 
structurally complex, we hypothesized that detecting deglycosylated CD133 may 
provide a more accurate and effective approach to targeting CD133 for imaging 
and therapy of lethal AVPC. To develop an improved antibody, we used antibody 
phage display to identify a human scFv, termed HA10. HA10 is selective for a 
glycosylation-independent epitope on the EC2 domain of CD133, providing the 
ability to detect both glycosylated and deglycosylated CD133. When compared to 
the commercial antibody, AC133, HA10 detected CD133 at similar or better levels 
in all assays tested to date. Notably, HA10 identified more CD133 in assays which 
relied heavily on maintaining the natural antigen structure, such as flow cytometry, 
suggesting that there is a small population of cells that are masked by glycosylation 
and are undetectable using commercial antibodies. After characterization, HA10 
was further developed into a full-length human IgG, termed HA10 IgG, and used 
for imaging preclinical models of PCa.      
99 
 
HA10 IgG displayed diagnostic potential in CD133-expressing preclinical models 
of PCa 
 HA10 IgG was labeled with a NIR probe or 89Zr and used for fluorescent 
imaging or PET imaging, respectively. Fluorescent imaging and PET imaging were 
performed in subcutaneous and metastatic tumor models. In the subcutaneous 
model, both probes displayed high selectivity and specificity for CD133pos tumors 
between 2 to 3 days post-injection. Tumor localization was observed at 24 hours 
post-injection, however, there was still a significant amount of probe in circulation 
at that time which leads to decreased contrast in the image. Alternatively, majority 
of the background signal was distributed or cleared between 48-72 hours, 
indicating that there is an optimal time frame for imaging after probe administration. 
Ex vivo biodistribution with the PET imaging probe confirmed these results by 
demonstrating a high concentration of 89Zr remaining in the blood at 24 hours post-
injection.  
Similar selectivity for CD133 was observed in the metastatic models, 
however, there were some metastatic lesions during the PET imaging studies that 
exhibited much lower tumoral uptake signals compared to other lesions within the 
same mouse. In general, spinal and mandibular lesions displayed better uptake 
than limb lesions. Since CD133 expression was confirmed by IHC after imaging 
and tumor size between mandibular tumors and spinal tumors was highly variable, 
we believe that vascularization and/or the tumor microenvironment may play a 
critical role in determining how well the probe is distributed to the lesion and will 
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likely affect the efficacy of the probe. Additionally, since 89Zr is known to be bone 
seeking, it is possible that the tumor signal is masked by non-specific accumulation 
of the radioisotope to the bone. Other radioisotopes will need to be investigated to 
assess whether the bone-seeking nature of 89Zr is interfering with the diagnostic 
potential of HA10 IgG.          
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Future Directions 
What is the therapeutic potential of HA10 IgG? 
 Numerous clinical trials using alpha- and beta- particle radiolabeled J591 to 
treat CRPC are currently underway (75, 214-218), however, our studies show that 
PSMA is not expressed in a subset of advanced CRPC patients. Thus, we 
hypothesize that a proportion of the patients in these trials which display an AR-
/NE+ phenotype will not respond to a PSMA-targeted therapy. Alternatively, our 
preliminary analyses of HA10 IgG suggest that its ability to fill the void of targeted 
agents for AR-/NE+ AVPC patients. The selectivity and specificity of HA10 IgG 
provides a rationale for studying it as a radioimmunotherapy agent for targeted 
treatment of AR-/NE+ AVPC. At this time, there is no evidence that HA10 IgG 
induces any antibody-dependent cellular cytotoxicity, although this phenomenon 
was never thoroughly investigated in these studies. Short term exposure to the 
labeled HA10 IgG for imaging studies revealed no decline in overall mouse health 
in vivo or cell toxicity in vitro. Additionally, previous research in CD133 knockout 
mice showed that the antigen CD133 was not critical to the overall viability of the 
mouse (93, 219), however, these same studies also indicated that CD133 is 
expressed in hematopoietic stem cells and may be critical for retinal function. 
Future therapeutic studies are needed to assess the therapeutic potential of HA10 
IgG and should adequately monitor adverse effects related to myelosuppression 
and vision loss.  
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Similarly, despite the fact that CD133 represents a promising target for 
imaging and therapeutic intervention of AR-/NE+ AVPC, it is still subject to various 
resistance mechanisms like any other protein. For example, since CD133 is not 
essential for cell viability (93) and CD133pos cells are documented to give rise to 
CD133neg cell populations (149), it is reasonable to assume that a tumor which 
originally expressed CD133 would adapt to preferentially produce HA10 IgG-
resistant CD133neg tumors. Furthermore, CD133 currently has 7 different defined 
isoforms and 6 more potential isoforms that are produced by alternative splicing 
(220). Mechanisms of antibody resistance may also emerge through alterations on 
the epitope in which the antibody binds. Future studies are required to directly 
identify where HA10 IgG is binding on the EC2 domain of CD133 and determine 
whether any of the previously described isoforms are already lacking this 
associated epitope.                     
How is CD133 regulated and does it directly drive more aggressive disease? 
 The physiologic function of CD133 in normal biology and the progression of 
cancer remains elusive. Understanding the molecular underpinnings of how 
CD133 is regulated and drives aggressive disease would provide more insight into 
the diagnostic and therapeutic potential of CD133-targeted agents such as HA10 
IgG. While this research did not focus on understanding CD133 regulation and 
signaling, some preliminary research was performed to investigate which 
pathways may affect CD133 expression. The first and most frequently referenced 
pathway was the Wnt signaling pathway. To interrogate this pathway, PC3 and 
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CWR-R1-EnzR cells were treated for 72 hours with 20 ng/ml of Wnt3a. RNA was 
extracted from these cell lines and qPCR was performed to evaluate CD133 
expression. Interestingly, CD133 expression was significantly increased in CWR-
R1-EnzR cells (Figure 23A), but not PC3 cells (Figure 23B), indicating that 
differences in these cell lines results in different CD133 regulation. Similar results 
were observed when cells were transduced with the BAMBI gene which encodes 
for a transmembrane glycoprotein related to the type I receptors of the 
transforming growth factor-beta (TGFβ) family (Figure 24A and 24B). Despite the 
fact that TGFβ has been documented to induce CD133 expression in colon cancer 
and PCa (221, 222), this is the first evidence to suggest that BAMBI specifically 
may play a role in CD133 regulation. More research is needed to investigate these 
pathways and identify if they are directly regulating CD133 expression and how 
this all correlates to more aggressive disease.         
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Figure 23. Addition of Wnt3a to PCa cell lines produces variable CD133 
expression in different PCa cell lines. A) CWR-R1-EnzR cells and B) PC3 
cells were stimulated with 20 ng/mL Wnt3a for 72 hours. qPCR was used to 
determine relative mRNA levels of CD133. 
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Figure 24. Transduction of BAMBI into PCa cell lines produces variable 
CD133 expression in different PCa cell lines. A) CWR-R1-EnzR cells and B) 
PC3 cells were stably transduced with lentivirus to produce BAMBI. qPCR was 
used to determine relative mRNA levels of CD133 and verify BAMBI expression. 
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